<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0131">
    <title>112 Hepatitis B and D Viruses*</title>
    <sect1 id="ch0131s0001">
      <title>112 Hepatitis B and D Viruses*</title>
      <anchor id="ch0131s0001a0001"/>
      <anchor id="ch0131s0000a0001"/>
      <anchor id="ch0131s0000a0002"/>
      <para id="ch0131s0000p0001" role="chapterAuthor">ELEANOR A. POWELL AND YI-WEI TANG</para>
      <sect2 id="ch0131s0001s0001">
        <title>HEPATITIS B VIRUS</title>
        <anchor id="ch0131s0001a0002"/>
        <anchor id="ch0131s0000a0003"/>
      </sect2>
    </sect1>
    <sect1 id="ch0131s0002">
      <title>Taxonomy</title>
      <anchor id="ch0131s0002a0001"/>
      <anchor id="ch0131s0000a0004"/>
      <para id="ch0131s0000p0002">Hepatitis B virus (HBV), which was discovered in blood specimens from Aboriginal Australians in 1965 (<link linkend="ch0131s0000li0001">1</link>), is an enveloped DNA virus in the genus <emphasis>Orthohepadnavirus</emphasis> of the <emphasis>Hepadnaviridae</emphasis> family. HBV has a narrow host range and infects only species closely related to humans, such as gibbons and several monkey species (<link linkend="ch0131s0000li0002">2</link>). As with other viruses in this family, the HBV genome is partially double stranded. It has a circular DNA molecule that replicates via an RNA intermediate. The replication of HBV DNA by reverse transcription is unique for human DNA viruses (<link linkend="ch0131s0000li0002">2</link>).</para>
    </sect1>
    <sect1 id="ch0131s0003">
      <title>Description of the Agent</title>
      <anchor id="ch0131s0003a0001"/>
      <anchor id="ch0131s0000a0005"/>
      <para id="ch0131s0000p0003">HBV is a 42-nm, partially double-stranded DNA virus that replicates in the nucleus of the host cell. HBV-infected cells have no cytopathic features because the virus causes little damage to the host cell (<link linkend="ch0131s0000li0002">2</link>). The virion is composed of HBsAg embedded in a lipid membrane surrounding a viral nucleocapsid core. The complete virus particle is known as the Dane particle, after its discoverer (<link linkend="ch0131s0000li0003">3</link>). The viral nucleocapsid core is surrounded by a specific viral core protein (HBcAg) and encloses a single molecule of partially double-stranded DNA, hepatitis B e antigen (HBeAg), and a DNA-dependent polymerase (<anchor id="ch0131s0000a0006"/><link linkend="ch0131s0000a0010">Fig. 1A</link>). The terminology used to describe the various antigens and antibodies associated with HBV as they appear at different stages of infection is given in <anchor id="ch0131s0000a0007"/><link linkend="ch0131s0000a0013">Table 1</link>.</para>
      <para id="ch0131s0000p0004">HBV particles found in the sera of patients with active HBV infection reveal three distinct morphologic entities in varying proportions (<link linkend="ch0131s0000a0010">Fig. 1A</link> and B). The most abundant forms (by a factor of 10<superscript>4</superscript> to 10<superscript>6</superscript>) are the small, pleomorphic, spherical, noninfectious particles (17 to 25 nm in diameter). These noninfectious particles have a low buoyant density, reflecting the presence of lipids from the host cell membrane (<link linkend="ch0131s0000li0002">2</link>). Less numerous are the tubular or filamentous forms, which have diameters similar to those of the small particles. The third and least numerous particle is the complete HBV virion, with a diameter of approximately 42 to 47 nm (<link linkend="ch0131s0000li0003">3</link>). At present, there is no native cell culture system that supports the growth of HBV, though hepatocyte cell lines expressing NTCP receptors support replication (<link linkend="ch0131s0000li0004">4</link>–<link linkend="ch0131s0000li0006">6</link>).</para>
      <para id="ch0131s0000p0005">The HBV genome is approximately 3,200 bases and contains overlapping genes (<link linkend="ch0131s0000a0010">Fig. 1C</link>). There are four open reading frames in the complete minus strand. These genes encode the structural proteins (HBsAg and HBcAg), replicative proteins (polymerase and X protein), and regulatory proteins (HBeAg) (<link linkend="ch0131s0000li0007">7</link>). The genome is compact, and most sequences are essential for productive infection and are transcribed in more than one open reading frame (<link linkend="ch0131s0000li0002">2</link>).</para>
      <para id="ch0131s0000p0006">As shown in<anchor id="ch0131s0000a0008"/><link linkend="ch0131s0000a0029">Fig. 2</link>, HBV infection of hepatocytes is initiated by low-affinity attachment to heparin sulfate proteoglycan. Subsequent specific binding to the sodium taurocholate cotransporting polypeptide (NTCP), a hepatocyte-specific receptor (<link linkend="ch0131s0000li0008">8</link>, <link linkend="ch0131s0000li0009">9</link>), induces entry of the viral particle into its target cells (<link linkend="ch0131s0000li0004">4</link>, <link linkend="ch0131s0000li0010">10</link>). Important cofactors include epidermal growth factor and E-cadherin (<link linkend="ch0131s0000li0011">11</link>–<link linkend="ch0131s0000li0013">13</link>). The HBV virion is then taken up via clathrin-mediated endocytosis and uncoated (<link linkend="ch0131s0000li0014">14</link>, <link linkend="ch0131s0000li0015">15</link>). The partially double-stranded, relaxed circular DNA is converted by the host polymerase to a covalently closed circular DNA (cccDNA) template in the cell nucleus (<link linkend="ch0131s0000li0002">2</link>).</para>
      <para id="ch0131s0000p0007">Five viral mRNA transcripts are translated into HBV proteins (<link linkend="ch0131s0000li0016">16</link>). These viral mRNAs are transcribed from different promoter regions on the cccDNA template (<link linkend="ch0131s0000a0010">Fig. 1C</link>). The longest mRNA (pgRNA) acts as the template for genome replication and also the translation of core (HBcAg) and polymerase proteins (<link linkend="ch0131s0000li0002">2</link>). A second transcript of similar length serves as a template for HBeAg. The third transcript encodes the pre-S1 region, pre-S2 region, and S region and is used for HBsAg production. A fourth transcript, also used for HBsAg production, encodes only the pre-S2 region and the S region. The smallest mRNA codes for the X protein, which is responsible for transactivating transcription.</para>
      <figure id="ch0131s0000f0001"><title><anchor id="ch0131s0000a0009"/><phrase role="figureLabel"><anchor id="ch0131s0000a0010"/><link linkend="ch0131s0000a0006">FIGURE 1</link></phrase> <emphasis role="strong">(A)</emphasis> The intact infectious HBV virion and the empty particles are shown. The two HBV particles (right) composed of HBsAg are shown as an elongated or tubular particle and as a spherical particle. These particles vastly outnumber the virions. (Designed by the University of Kansas Graphic Design Department, 2009.) <emphasis role="strong">(B)</emphasis> Electron micrograph of serum showing the presence of three distinct morphologic entities: 17- to 25-nm-diameter pleomorphic, spherical particles <emphasis role="strong">(a)</emphasis>, tubular or filamentous forms with diameters similar to those of the small particles <emphasis role="strong">(b)</emphasis>, and 42- to 47-nm-diameter double-shelled spherical particles representing the HBV virion (Dane particle) <emphasis role="strong">(c).</emphasis> Magnification, ×105. <emphasis role="strong">(C)</emphasis> Diagrammatic representation of HBV coding regions. The functioning genome is a double-stranded circular DNA molecule, shown in the middle. RNA transcripts (arrows) are generated using both the plus-strand [(+)Strand] and minus-strand [(−)Strand] DNA templates. The largest transcript codes for the viral polymerase, shown around the genome as the P transcript. The transcript for surface antigen (S) is produced as three separate transcripts, pre-S1, pre-S2, and S. The core protein is translated from the C transcript. HBeAg is encoded within the HB core gene. The transactivating protein is coded by the X transcript. (Designed by the University of Kansas Graphic Design Department, 2009.)
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f08.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0008">The pgRNA is transcribed from the cccDNA in the nucleus and then moves into the cytoplasm of the host cell, where it serves as the template for the polymerase enzyme and the core protein. At the same time, the reverse transcriptase domain of the polymerase converts the pgRNA to a new circular DNA molecule (<link linkend="ch0131s0000li0004">4</link>). Early in infection, some of these newly synthesized genomes from the cytoplasm circulate back to the nucleus to build up and maintain the pool of cccDNA (<link linkend="ch0131s0000li0002">2</link>). The pgRNA and the polymerase protein are packaged into immature core particles, where the reverse transcriptase enzyme synthesizes a new circular DNA molecule. At this point the virion is considered mature. These particles are then transported to the HBsAg in the endoplasmic reticulum of the host cell and exported from the cell.</para>
      <anchor id="ch0131s0000a0011"/>
      <beginpage pagenum="2164"/>
      <para id="ch0131s0000p0009">The envelope proteins of HBsAg are made up of three polypeptides encoded by the S/pre-S region of the HBV genome (<link linkend="ch0131s0000a0010">Fig. 1C</link>). The major protein is the smallest peptide. It is encoded by the S region and is a glycosylated polypeptide. The middle protein, encoded by the S and the pre-S2 regions, has an additional glycosylation site. The large S protein consists of 389 to 400 amino acids encoded by the pre-S1, pre-S2, and S regions of the genome. The production of HBsAg exceeds what is needed for virion production, and this excess antigen circulates in the blood of infected individuals as three different kinds of particles: mature virions containing major, middle, and large surface proteins; spherical subviral particles containing the major protein only; and filamentous particles containing the middle and major surface proteins (<link linkend="ch0131s0000li0017">17</link>). Noninfectious subviral particles may persist in the serum for variable periods after initial infection, can outnumber infectious virions by a factor of 100,000, and in some patients can be as high as 10<superscript>13</superscript> per ml (<link linkend="ch0131s0000li0017">17</link>). Thus, these HBsAg particles are used as a diagnostic marker in serum to detect active viral replication and monitor therapeutic response (<link linkend="ch0131s0000li0017">17</link>–<link linkend="ch0131s0000li0023">23</link>).</para>
      <anchor id="ch0131s0000a0012"/>
      <beginpage pagenum="2165"/>
      <table id="ch0131s0000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0131s0000a0013"/><link linkend="ch0131s0000a0007">TABLE 1</link></phrase></emphasis> HBV markers in different stages of infection and convalescence<superscript><link linkend="ch0131s0000a0020"><emphasis>a</emphasis></link></superscript><anchor id="ch0131s0000a0014"/>
</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="center">Stage of infection</phrase>
              </entry>
              <entry><phrase role="center">Molecular marker: HBV DNA</phrase>
              </entry>
              <entry><phrase role="center">Protein antigen markers</phrase>
              </entry>
              <entry><phrase role="center">HBV-specific antibody markers</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Anti-HBc</phrase>
              </entry>
              <entry><phrase role="center">Anti-HBe</phrase>
              </entry>
              <entry><phrase role="center">Anti-HBs</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">HBsAg</phrase>
              </entry>
              <entry><phrase role="center">HBeAg</phrase>
              </entry>
              <entry><phrase role="center">IgM</phrase>
              </entry>
              <entry><phrase role="center">Total</phrase>
              </entry>
            </row>
            <row>
              <entry>Susceptible</entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Early incubation</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Late incubation</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−/+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Acute infection</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>HBsAg-negative window in acute infection</entry>
              <entry><phrase role="center">− (&lt;10<superscript>3</superscript> IU/ml)</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Recent infection<superscript><link linkend="ch0131s0000a0021"><emphasis>b</emphasis></link></superscript><anchor id="ch0131s0000a0015"/></entry>
              <entry><phrase role="center">−/+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">++</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+++</phrase>
              </entry>
            </row>
            <row>
              <entry>Remote resolved infection<superscript><link linkend="ch0131s0000a0022"><emphasis>c</emphasis></link></superscript><anchor id="ch0131s0000a0016"/></entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry>Immune tolerant carrier</entry>
              <entry><phrase role="center">+++</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Immune active carrier</entry>
              <entry><phrase role="center">++ (&gt;10<superscript>5</superscript> IU/ml)</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−/+</phrase>
              </entry>
              <entry><phrase role="center">−/+</phrase>
              </entry>
              <entry><phrase role="center">+++</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Inactive carrier</entry>
              <entry><phrase role="center">− (&lt;10<superscript>3</superscript> IU/ml)</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>HBeAg-negative chronic infection<superscript><link linkend="ch0131s0000a0023"><emphasis>d</emphasis></link></superscript><anchor id="ch0131s0000a0017"/></entry>
              <entry><phrase role="center">++</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>HBsAg variant infection<superscript><link linkend="ch0131s0000a0024"><emphasis>e</emphasis></link></superscript><anchor id="ch0131s0000a0018"/></entry>
              <entry><phrase role="center">++/+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Chronic low-level infection<superscript><link linkend="ch0131s0000a0022"><emphasis>c</emphasis></link></superscript></entry>
              <entry><phrase role="center">−/+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+/−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry>Vaccination response</entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry>Recent vaccination<superscript><link linkend="ch0131s0000a0025"><emphasis>f</emphasis></link></superscript><anchor id="ch0131s0000a0019"/></entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para id="ch0131s0000p0010" role="table-footnote"><superscript><link linkend="ch0131s0000a0014"><emphasis>a</emphasis></link></superscript><anchor id="ch0131s0000a0020"/>−, not detected; +, detected; −/+, sometimes detected; ++, detected at high levels; +++, detected at very high levels; HBsAg, complex antigen found on surface of HBV and on 20-nm-diameter particles and tubular forms; HBcAg, antigen associated with 27-nm-diameter core of HBV; HBeAg, protein that results from the proteolytic cleavage of the precore/core protein by cellular proteases and secreted as soluble protein in serum.</para>
      <para id="ch0131s0000p0011" role="table-footnote"><superscript><link linkend="ch0131s0000a0015"><emphasis>b</emphasis></link></superscript><anchor id="ch0131s0000a0021"/>This description can be applied to early convalescence and to individuals that remain HBV DNA positive for prolonged periods in the absence of HBsAg.</para>
      <para id="ch0131s0000p0012" role="table-footnote"><superscript><link linkend="ch0131s0000a0016"><emphasis>c</emphasis></link></superscript><anchor id="ch0131s0000a0022"/>The term “remote infection” can be applied to individuals with anti-HBc in the absence of other serologic markers, including DNA. These patients may or may not have anti-HBs. There is evidence that these patients may reactivate HBV during immunosuppression or treatment for hepatitis C virus.</para>
      <para id="ch0131s0000p0013" role="table-footnote"><superscript><link linkend="ch0131s0000a0017"><emphasis>d</emphasis></link></superscript><anchor id="ch0131s0000a0023"/>Precore or core promoter region mutations may result in HBeAg-negative results despite high HBV DNA levels.</para>
      <para id="ch0131s0000p0014" role="table-footnote"><superscript><link linkend="ch0131s0000a0018"><emphasis>e</emphasis></link></superscript><anchor id="ch0131s0000a0024"/>HBsAg variants or escape mutants may not be detected by immunoassays.</para>
      <para id="ch0131s0000p0015" role="table-footnote"><superscript><link linkend="ch0131s0000a0019"><emphasis>f</emphasis></link></superscript><anchor id="ch0131s0000a0025"/>HBsAg can be detected in serum for 18 days after vaccination, and up to 52 days in dialysis patients.</para>
      <para id="ch0131s0000p0016">Two additional HBV-specific proteins play a key role in diagnostic testing. HBcAg and HBeAg have different antigenic specificities, and both can be distinguished from HBsAg. HBcAg is a polypeptide encoded by the C gene of HBV and is translated from the pregenomic mRNA (<link linkend="ch0131s0000a0010">Fig. 1C</link>). The precore sequence within the C ORF is upstream of the sequence that codes for HBcAg and contains the start codon for HBeAg translation (<link linkend="ch0131s0000li0020">20</link>, <link linkend="ch0131s0000li0024">24</link>). Because of the different start codons, the two proteins, HBcAg and HBeAg, are antigenically unrelated. HBeAg lacks the viral DNA-binding domain found on HBcAg. The first 29 amino acid residues of the HBeAg are encoded in the precore region of the C gene. This part of HBeAg directs the protein to the host endoplasmic reticulum. In the endoplasmic reticulum this “homing” portion of the protein is cleaved off, and HBeAg is released from the host cell to the blood. In the blood HBeAg is a soluble protein or is bound to albumin, α-1-antitrypsin, or immunoglobulin. It is a dependable marker for the presence of intact virions, indicating high infectivity. In some HBV strains, a mutation at the end of the precore region of the C gene results in a stop codon which prevents the translation of HBeAg. These precore mutants contribute to the pathogenesis of chronic HBV disease, leading to acute exacerbation of disease (<link linkend="ch0131s0000li0020">20</link>, <link linkend="ch0131s0000li0025">25</link>). Other HBV gene mutations have been observed in the core, core promoter, envelope, and polymerase regions. The envelope protein variants become relevant, because some of them lead to antigenic changes that are not recognized by HBs antibody. These viruses, called escape HBV mutants, are resistant to HBsAg vaccine-induced neutralizing antibody and do not respond to hepatitis B immunoglobulin (HBIG) therapy (<link linkend="ch0131s0000li0020">20</link>, <link linkend="ch0131s0000li0026">26</link>, <link linkend="ch0131s0000li0027">27</link>).</para>
    </sect1>
    <sect1 id="ch0131s0004">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0131s0004a0001"/>
      <anchor id="ch0131s0000a0026"/>
      <para id="ch0131s0000p0017">HBV infections are prevalent around the world and represent a global public health problem. Roughly 30% of the world’s population shows serological evidence of current or past HBV infection. The World Health Organization (WHO) estimates that approximately 820,000 people died in 2019 (the most recent year for which data are available) as a result of acute or chronic HBV, and 1.5 million people were newly infected with chronic HBV (<link linkend="ch0131s0000li0028">28</link>). Unlike many other diseases of public health importance, mortality due to HBV is increasing (<link linkend="ch0131s0000li0028">28</link>, <link linkend="ch0131s0000li0029">29</link>).</para>
      <para id="ch0131s0000p0018">The most common modes of HBV transmission are vertical transmission (mother to child perinatally), early childhood infections from close contact with infected individuals, sexual activity (both heterosexual and male homosexual), and injection drug use or other physical contact with infected body fluids (occupational exposure, contaminated blood products, etc.) (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>). HBV is not transmitted by casual activities such as talking, hand holding, or hugging, by ingestion of food or water, or from a cough or sneeze.</para>
      <anchor id="ch0131s0000a0027"/>
      <beginpage pagenum="2166"/>
      <figure id="ch0131s0000f0002"><title><anchor id="ch0131s0000a0028"/><phrase role="figureLabel"><anchor id="ch0131s0000a0029"/><link linkend="ch0131s0000a0008">FIGURE 2</link></phrase> Schematic representation of the HBV lifecycles in hepatocytes NTCP sodium taurocholate cotransporting polypeptide. Reprinted from reference <link linkend="ch0131s0000li0049">49</link> with permission.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f09.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0019">The majority of HBV-infected individuals live in Asia or Africa (<anchor id="ch0131s0000a0030"/><link linkend="ch0131s0000a0034">Fig. 3A</link>). Approximately one-fourth of adults who were infected with HBV as children experience serious complications from liver cirrhosis and/or hepatocellular carcinoma (HCC) linked to chronic HBV (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0030">30</link>). These regions are disproportionately affected by HCC, with 80% of deaths due to HCC occurring in Africa and East Asia (<link linkend="ch0131s0000li0031">31</link>). In the United States, it was estimated that 21,600 new cases occurred in 2018, and approximately 862,000 individuals were living with HBV infection in 2016 (<ulink url="https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview">https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview</ulink>, accessed 17 January 2022). In the United States, most infections are in adults, in whom the risk of chronic infection is lower. In contrast, outside the United States, perinatal exposure is more common and leads to chronic HBV infections (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0032">32</link>).</para>
      <para id="ch0131s0000p0020">In 2016, the WHO set a goal to eliminate HBV as a public health threat by 2030 (<link linkend="ch0131s0000li0028">28</link>). One of the primary strategies to meet this goal is to reach 50% coverage with a birth dose of the HBV vaccine by 2020 and 90% by 2030. As of 2019, the global coverage with a first vaccine dose at birth was 43%. There has been a decrease in the prevalence of HBV in children under 5 from 4.7% in the pre-vaccine era to 1.3% in 2015 (<link linkend="ch0131s0000li0029">29</link>).</para>
    </sect1>
    <sect1 id="ch0131s0005">
      <title>Clinical Significance</title>
      <anchor id="ch0131s0005a0001"/>
      <anchor id="ch0131s0000a0031"/>
      <para id="ch0131s0000p0021">HBV infects hepatocytes, leading to either an acute infection that resolves or a chronic infection that lasts for years. In infected individuals, subclinical hepatitis presents as a mild disease without symptoms or jaundice. It is not uncommon for many HBV-infected people to be asymptomatic early in disease. Nevertheless, some patients may have nonspecific symptoms such as abdominal pain, nausea without jaundice (anicteric hepatitis), or nausea with jaundice (icteric hepatitis). HBV infections can result in the complete recovery of the patient, fulminant hepatitis with mortality, or a chronic viral infection. Progression from acute to chronic HBV varies with age at infection, occurring in approximately 90% of perinatal infections, 16 to 30% of infections occurring in childhood, and &lt;5% of adult infections (<link linkend="ch0131s0000li0033">33</link>).</para>
      <para id="ch0131s0000p0022">The incubation period of acute HBV infection ranges from 6 weeks to 6 months. During this time the infection can be symptomatic or asymptomatic. Newborns infected with HBV usually have chronic, asymptomatic infections, while older children and adults are typically symptomatic during a primary infection (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>). The symptoms of acute HBV infection are often mild but sometimes include physical signs such as jaundice, dark urine, clay-colored stools, and hepatomegaly (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0034">34</link>). Some patients experience weight loss, right upper quadrant pain, and a tender, enlarged liver. Serum alanine transaminase (ALT) levels are often elevated, and patients are HBsAg positive (<link linkend="ch0131s0000li0035">35</link>). Acute HBV infections are usually self-limited, and most patients recover completely after specific antibodies (anti-HBs) clear the virus (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0034">34</link>). A small percentage of infected adults will develop fulminant acute hepatitis, characterized by coagulopathy, symptoms lasting longer than 4 weeks, or signs of acute liver failure (<link linkend="ch0131s0000li0036">36</link>).</para>
      <anchor id="ch0131s0000a0032"/>
      <beginpage pagenum="2167"/>
      <figure id="ch0131s0000f0003"><title><anchor id="ch0131s0000a0033"/><phrase role="figureLabel"><anchor id="ch0131s0000a0034"/><link linkend="ch0131s0000a0030">FIGURE 3</link></phrase> <emphasis role="strong">(A)</emphasis> Global HBsAg endemicity (1957–2013). Reprinted from Schweitzer et al. with permission (<link linkend="ch0131s0000li0030">30</link>). <emphasis role="strong">(B)</emphasis> Distribution of major HBV genotypes by country. Pie charts represent genotype proportion in each country. Reprinted from Velkov et al. with permission (<link linkend="ch0131s0000li0107">107</link>).
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f10.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0023">Patients who continue to have detectable HBsAg or detectable HBV DNA in serum for at least 6 months after infection are considered to have chronic HBV infections (<link linkend="ch0131s0000li0034">34</link>). Though terminology has varied over time and between international societies (<link linkend="ch0131s0000li0036">36</link>), four phases of chronic HBV disease are commonly recognized: (i) immune tolerant, (ii) immune active, (iii) inactive, and (iv) reactivation (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0033">33</link>, <link linkend="ch0131s0000li0034">34</link>, <link linkend="ch0131s0000li0037">37</link>, <link linkend="ch0131s0000li0038">38</link>). The European Association for the Study of the Liver designates five stages: phase 1, HBeAg-positive chronic HBV infection; phase 2, HBeAg-positive chronic hepatitis B; phase 3, HBeAg-negative chronic HBV infection; phase 4, HBeAg-negative chronic hepatitis B; and phase 5, HBsAg-negative phase (<link linkend="ch0131s0000li0036">36</link>). It is important to note that these phases are not always consecutive and patients may not experience all phases.</para>
      <anchor id="ch0131s0000a0035"/>
      <beginpage pagenum="2168"/>
      <para id="ch0131s0000p0024">Patients with perinatally acquired HBV usually remain in the immune tolerant phase (or phase 1, HBeAg-positive chronic HBV infection) through adolescence. This phase is characterized by very high levels of virus and detectable HBeAg, but the absence of clinical or histologic signs of liver disease (<link linkend="ch0131s0000li0036">36</link>, <link linkend="ch0131s0000li0039">39</link>). Symptoms of chronic HBV are generally nonspecific and may be unrecognized for years, though patients in this phase are highly infectious due to the high viral load.</para>
      <para id="ch0131s0000p0025">Most HBV-infected individuals progress to the immune active phase (or phase 2, HBeAg-positive chronic hepatitis B), in which a liver biopsy shows inflammation with fibrosis, thus the term “active.” This pathology results from a persistent immune response to the HBV proteins on infected hepatocytes. Most patients are able to mount enough of an immune response to HBV that HBeAg seroconversion occurs and HBV DNA replication decreases, entering the inactive carrier phase (phase 3, HBeAg-negative chronic HBV infection). This phase is characterized by less inflammation, as determined by liver biopsy, normal liver enzyme levels, and decreased HBV viral loads. These patients have a lower risk for HCC (<link linkend="ch0131s0000li0018">18</link>). From either the immune active or inactive carrier phase, patients can enter phase 4, HBeAg-negative chronic hepatitis B, which is characterized by higher levels of HBV DNA, elevated liver enzymes, and liver fibrosis (<link linkend="ch0131s0000li0036">36</link>). Alternatively, patients in the inactive carrier phase can remain positive for HBsAg indefinitely, although some HBsAg-positive patients spontaneously convert to HBsAg negative after the appearance of anti-HBs. Many of these patients continue to have detectable HBV DNA and are considered to have “occult HBV” and to be in phase 5, HBsAg-negative phase (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0036">36</link>, <link linkend="ch0131s0000li0037">37</link>). HBsAg seroconversion occurs at a rate of 1 to 3% of inactive carriers per year (<link linkend="ch0131s0000li0036">36</link>, <link linkend="ch0131s0000li0039">39</link>).</para>
      <para id="ch0131s0000p0026">Chronic HBV infection is associated with an increased risk for HCC (<link linkend="ch0131s0000li0037">37</link>, <link linkend="ch0131s0000li0040">40</link>, <link linkend="ch0131s0000li0041">41</link>). During HBV infection, the viral DNA randomly integrates into the hepatocyte genome. Over time this results in high levels of integrated viral DNA in host cells that can persist for years. Since the viral DNA integrates randomly, the number of integration sites also increases over time (<link linkend="ch0131s0000li0034">34</link>, <link linkend="ch0131s0000li0042">42</link>). Some of this randomly integrated viral DNA can activate cellular proto-oncogenes or suppress the regulation of gene expression (<link linkend="ch0131s0000li0041">41</link>). Integration around the telomerase reverse transcriptase (TERT) gene locus is particularly associated with HCC development (<link linkend="ch0131s0000li0042">42</link>, <link linkend="ch0131s0000li0043">43</link>). In addition, some HBV proteins, such as the X protein and the truncated pre-S/S protein, can result in endoplasmic reticulum stress and are potent transactivators of cellular genes (<link linkend="ch0131s0000li0043">43</link>–<link linkend="ch0131s0000li0045">45</link>). Recent data suggest that microRNAs and other noncoding RNAs also play a role in HBV-associated oncogenesis (<link linkend="ch0131s0000li0042">42</link>, <link linkend="ch0131s0000li0046">46</link>). Likewise, several other factors have been associated with the development of HCC, such as smoking, alcohol consumption, non-alcoholic fatty liver disease, infections with other hepatotropic viruses (hepatitis C), and mycotoxins (aflatoxin) (<link linkend="ch0131s0000li0040">40</link>, <link linkend="ch0131s0000li0047">47</link>).</para>
      <para id="ch0131s0000p0027">Safe and effective vaccines against HBV have been available since 1981. The complete HBV vaccination series is protective in &gt;95% of infants, children, and young adults (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0032">32</link>). Vaccine-induced protection lasts at least 20 years and may be lifelong. Universal vaccination is recommended at birth, in childhood, and for adults in high-risk settings. Nonimmune individuals with a known or suspected exposure to HBV should be given HBV vaccine as soon as possible after the exposure, in addition to HBIG. In January 2018, updated recommendations for the prevention of HBV infection in the United States from the Advisory Committee on Immunization Practices were released by the Centers for Disease Control and Prevention (CDC) (<ulink url="https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf">https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf</ulink>, accessed 17 January 2022). Two single-antigen vaccines (HBsAg only) and two combination vaccines (HBsAg in combination with other vaccines) were included. These vaccines require three spaced doses, at 0, 1, and 6 months. In March 2018, a more immunogenic adjuvanted HBV vaccine was approved for use in nonpregnant adults, which requires only two doses, 4 weeks apart, and may be more immunogenic for patients with compromised immune systems. Information on the Heplisav-B vaccine is available on the CDC website (<ulink url="https://www.cdc.gov/vaccines/schedules/vacc-updates/heplisav-b.html">https://www.cdc.gov/vaccines/schedules/vacc-updates/heplisav-b.html</ulink>, accessed 17 January 2022) (<link linkend="ch0131s0000li0038">38</link>, <link linkend="ch0131s0000li0048">48</link>).</para>
      <para id="ch0131s0000p0028">Chronic HBV infections should be treated with lifelong antiviral drugs. Historically, the goals of treating chronic HBV are to suppress viral replication and slow the progression of liver damage (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0050">50</link>). With the advent of new, curative therapies for patients with hepatitis C, a discussion has taken place to define what it means to be “cured” of chronic HBV (<link linkend="ch0131s0000li0039">39</link>, <link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0051">51</link>, <link linkend="ch0131s0000li0052">52</link>). Typical goals of treatment include reduction of HBV viral load, HBeAg seroconversion, liver enzyme normalization, and ideally HBsAg seroconversion (<link linkend="ch0131s0000li0036">36</link>). At present, drugs to treat HBV are classified into two categories, the immune modulating interferons and the nucleoside/nucleotide analogs. The FDA has approved the nucleoside/nucleotide analogs adefovir, entecavir, lamivudine, tenofovir, emtricitabine, and telbivudine for use in the United States (<link linkend="ch0131s0000li0034">34</link>, <link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0050">50</link>, <link linkend="ch0131s0000li0053">53</link>). In late 2016, the FDA approved tenofovir alafenamide, a tenofovir prodrug, for treatment of adults with chronic HBV infection with compensated liver disease. Since tenofovir alafenamide has greater plasma stability and more efficiently delivers tenofovir to hepatocytes, it can be given at a lower dose once a day, improving renal and bone laboratory safety parameters (<link linkend="ch0131s0000li0054">54</link>, <link linkend="ch0131s0000li0055">55</link>). Of the nucleoside/nucleotide analogs, tenofovir, tenofovir alafenamide, and entecavir are typically preferred due to higher barriers to resistance (<link linkend="ch0131s0000li0033">33</link>, <link linkend="ch0131s0000li0036">36</link>).</para>
      <para id="ch0131s0000p0029">With the discovery of NTCP as an HBV receptor (<link linkend="ch0131s0000li0004">4</link>–<link linkend="ch0131s0000li0007">7</link>), HBV entry inhibitors are now under investigation as a novel class of antivirals with potential for viral control and possibly cure (<link linkend="ch0131s0000li0052">52</link>, <link linkend="ch0131s0000li0056">56</link>). A pre-S1 peptide (i.e., Myrcludex B) derived from the HBV envelope, and specifically binding to the receptor, has been approved for hepatitis D treatment by the European Union, and trials for HBV monoinfection are ongoing (<link linkend="ch0131s0000li0057">57</link>). Additionally, clinical trials are under way for drugs targeting other steps of the HBV replication cycles, including HBsAg secretion and core protein assembly (<link linkend="ch0131s0000li0058">58</link>). Immune system stimulating agents, including therapeutic vaccines,Toll-like receptor agonists, PD-1 inhibitors, genetically modified T-cells, and siRNA therapy, are also being developed (<link linkend="ch0131s0000li0059">59</link>, <link linkend="ch0131s0000li0060">60</link>).</para>
    </sect1>
    <sect1 id="ch0131s0006">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0131s0006a0001"/>
      <anchor id="ch0131s0000a0036"/>
      <para id="ch0131s0000p0030">HBV infection is diagnosed by serologic and molecular markers detected in serum or plasma. All FDA-approved assays have specific specimen requirements defined in their package inserts. These requirements state the acceptable specimen types and describe the processing and storage of the specimen. In general, HBV antigens and antibodies are stable at room temperature for days, can be stored at 4°C for months, and can be frozen at −20 to −70°C for years. Although HBV markers are stable in serum stored at −70°C, repetitive freezing and thawing can lead to their degradation. The use of hemolyzed samples should be avoided due to the potential of these specimens to interfere with the detection signals used in immunoassays.</para>
      <anchor id="ch0131s0000a0037"/>
      <beginpage pagenum="2169"/>
      <para id="ch0131s0000p0031">Both serum and plasma (EDTA or acid-citrate-dextrose [ACD]) can be used for nucleic acid analysis (<link linkend="ch0131s0000li0061">61</link>). However, for consistent results, serial testing should be performed using the same sample type and the same kit whenever possible. Depending on the manufacturer’s instructions for the kit employed, serum or plasma should be separated from cells within 6 to 24 h and stored at 4°C for 3 to 7 days until tested. For long-term storage, serum or plasma should be kept at −70°C. Heparinized plasma is unacceptable for most nucleic acid analysis because heparin interferes with <emphasis>Taq</emphasis> polymerase-mediated PCR. There is evidence that HBV DNA is stable and detectable without a loss of sensitivity after multiple freeze-thaw cycles (<link linkend="ch0131s0000li0062">62</link>). Dried blood spots on filter paper and dried specimen storage transportation systems have been successfully used for HBV serology and nucleic acid testing (<link linkend="ch0131s0000li0063">63</link>–<link linkend="ch0131s0000li0065">65</link>). Oral fluids have also been used successfully (<link linkend="ch0131s0000li0066">66</link>, <link linkend="ch0131s0000li0067">67</link>). Useful information about many diagnostic tests can be found by consulting the FDA website and the specific year of test approval (<ulink url="http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm">http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm</ulink>, accessed 17 January 2022).</para>
      <para id="ch0131s0000p0032">The HBV virion is very hardy and remains infectious for at least 7 days and up to 22 days outside the host (<link linkend="ch0131s0000li0061">61</link>, <link linkend="ch0131s0000li0068">68</link>). Thus, spills or splashes should be cleaned using absorbent material and disinfected with an appropriate disinfectant. Decontamination should be carried out while wearing gloves. Laboratory personnel should regard all specimens as potentially infectious (<link linkend="ch0131s0000li0069">69</link>). The Occupational Safety and Health Administration (OSHA) standards for occupational exposure to blood-borne pathogens are designed to protect employees exposed to blood and other potentially infectious materials. OSHA mandates that all employees whose job requirements put them at risk for blood-borne pathogens be offered HBV vaccine at no cost. OSHA standards and additional safety recommendations can be found in the literature.</para>
    </sect1>
    <sect1 id="ch0131s0007">
      <title>Direct Detection</title>
      <anchor id="ch0131s0007a0001"/>
      <anchor id="ch0131s0000a0038"/>
      <para id="ch0131s0000p0033">The diagnosis of HBV uses a combination of tests (<link linkend="ch0131s0000li0059">59</link>, <link linkend="ch0131s0000li0070">70</link>, <link linkend="ch0131s0000li0071">71</link>). These assays detect specific HBV proteins, nucleic acid, and specific antibodies in plasma or serum (<anchor id="ch0131s0000a0039"/><link linkend="ch0131s0000a0044">Table 2</link>).</para>
      <sect2 id="ch0131s0007s0001">
        <title>Microscopy</title>
        <anchor id="ch0131s0007a0002"/>
        <anchor id="ch0131s0000a0040"/>
        <para id="ch0131s0000p0034">Electron microscopy for detection of HBV does not play a role in the diagnosis of disease. However, a liver biopsy may be used to assess the extent of histologic involvement as well as the response to therapy. Histologic examination is useful for distinguishing among acute viral hepatitis, chronic hepatitis, and cirrhosis.</para>
      </sect2>
      <sect2 id="ch0131s0007s0002">
        <title>Antigen</title>
        <anchor id="ch0131s0007a0003"/>
        <anchor id="ch0131s0000a0041"/>
        <para id="ch0131s0000p0035">Several HBV-specific proteins can be detected in patient specimens during infection. These are markers of active viral replication. The presence of HBsAg and/or HBeAg in serum occurs during primary infection and during chronic HBV infection (<link linkend="ch0131s0000a0013">Table 1</link>). HBsAg is located on the outer surface of the HBV particles, while HBeAg is translated from the precore mRNA of HBcAg (<link linkend="ch0131s0000a0010">Fig. 1C</link>). The function of HBeAg and its role in disease have not been clearly identified; however, the detection of this protein in serum indicates high viral replication. Both HBsAg and HBeAg are made in large excess by infected host cells and can be detected in serum during active infection (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0017">17</link>, <link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0072">72</link>). HBV-specific antigens in serum have been mainly detected by enzyme or chemiluminescence immunoassays. The presence of viral antigens in tissue can be determined through the use of immunohistochemistry.</para>
        <para id="ch0131s0000p0036">Diagnostic assays with high sensitivity and specificity are available to detect these HBV antigens.<link linkend="ch0131s0000a0013">Table 1</link> lists the biomarkers used to determine the stage of HBV disease. HBV antigens are detected by using solid-phase assays based on capture with a monoclonal antibody and then detected with a second antibody attached to a signal. These assays commonly use microparticles with different compositions and sizes and are usually performed on automated instruments (<link linkend="ch0131s0000li0018">18</link>, <link linkend="ch0131s0000li0073">73</link>). Antigen capture and detection reagents are specific for the major immunodominant region of HBsAg. Current detection methods use enzyme or chemiluminescence immunoassays to detect specific antigens (<link linkend="ch0131s0000a0044">Table 2</link>). Hepatitis B core-related antigen is considered an emerging marker for chronic HBV due to its correlation with intrahepatic cccDNA levels, but it currently remains a research tool (<link linkend="ch0131s0000li0074">74</link>–<link linkend="ch0131s0000li0076">76</link>).</para>
        <sect3 id="ch0131s0007s0001">
          <title>HBsAg</title>
          <anchor id="ch0131s0007a0004"/>
          <anchor id="ch0131s0000a0042"/>
          <para id="ch0131s0000p0037">The detection of HBsAg in serum plays a central role in establishing the diagnosis of HBV infection. Each HBsAg assay is approved by the FDA for diagnostic use only; for testing donors of blood, organs, and tissue only; or for both applications. The package insert should be consulted to determine what sample types have been approved for use with each HBsAg test (<link linkend="ch0131s0000a0044">Table 2</link>).</para>
          <para id="ch0131s0000p0038">The presence of HBsAg in the serum indicates that the patient is considered infectious. Patients who resolve an acute infection eventually produce anti-HBs (see “Serologic Tests” below). However, when HBsAg is present, anti-HBs can be negative in diagnostic tests because the antibody is bound to the HBsAg.</para>
          <para id="ch0131s0000p0039">For all commercially available diagnostic assays, any specimens that are nonreactive for HBsAg are considered negative and do not require further testing. In contrast, specimens reactive for HBsAg are often repeated to verify positive results. These repeatedly HBsAg-positive results are usually confirmed by a neutralization assay provided by the manufacturer consistent with FDA approval protocols. If the HBsAg-reactive serum is neutralized by the anti-HBs, then the specimen is considered positive for HBsAg. Conversely, if the anti-HBs does not neutralize the HBsAg, then the HBsAg test must be considered nonconfirmed. A new specimen should be requested and/or the patient should be tested for other markers of HBV infection such as IgM anti-HBc, total anti-HBc, and/or HBV DNA.</para>
          <para id="ch0131s0000p0040">All HBsAg assays are capable of detecting subnanogram amounts of protein with no loss of specificity (<link linkend="ch0131s0000li0046">46</link>, <link linkend="ch0131s0000li0048">48</link>). For diagnostic applications, this level of sensitivity is sufficient to detect the HBsAg in the sera of individuals with actively replicating HBV. However, a recent concern is that some assays cannot detect variants of HBsAg that have mutations within the major antigenic region of the protein. These mutant HBsAg proteins can be missed by some diagnostic assays (<link linkend="ch0131s0000li0018">18</link>, <link linkend="ch0131s0000li0026">26</link>, <link linkend="ch0131s0000li0077">77</link>), so initial testing should include the detection of antibodies to both HBsAg and HB core, and if needed, molecular assays should be used for confirmation (<link linkend="ch0131s0000li0018">18</link>).</para>
          <anchor id="ch0131s0000a0043"/>
          <beginpage pagenum="2170"/>
          <table id="ch0131s0000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0131s0000a0044"/><link linkend="ch0131s0000a0039">TABLE 2</link></phrase></emphasis> Commercial systems for serologic testing of HBV antigens and antibodies available in the United States
</title>
            
            <tgroup cols="7">
              <tbody>
                <row>
                  <entry><phrase role="center">Manufacturer</phrase>
                  </entry>
                  <entry><phrase role="center">Test</phrase>
                  </entry>
                  <entry><phrase role="center">Method<superscript><link linkend="ch0131s0000a0052"><emphasis>a</emphasis></link></superscript></phrase>
                    <anchor id="ch0131s0000a0045"/>
                  </entry>
                  <entry><phrase role="center">Analytes</phrase>
                  </entry>
                  <entry><phrase role="center">Acceptable specimens<superscript><link linkend="ch0131s0000a0053"><emphasis>b</emphasis></link></superscript></phrase>
                    <anchor id="ch0131s0000a0046"/>
                  </entry>
                  <entry><phrase role="center">Reportable range<superscript><emphasis><anchor id="ch0131s0000a0047"/><link linkend="ch0131s0000a0054">c</link>,<anchor id="ch0131s0000a0048"/><link linkend="ch0131s0000a0055">d</link></emphasis></superscript> (level for immunity; range)</phrase>
                  </entry>
                  <entry><phrase role="center">Approved uses<superscript><link linkend="ch0131s0000a0056"><emphasis>e</emphasis></link></superscript></phrase>
                    <anchor id="ch0131s0000a0049"/>
                  </entry>
                </row>
                <row>
                  <entry>Abbott Laboratories</entry>
                  <entry>Architect Next</entry>
                  <entry>CLIA</entry>
                  <entry>HBsAg<superscript><link linkend="ch0131s0000a0057"><emphasis>f</emphasis></link></superscript><anchor id="ch0131s0000a0050"/>, anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma (no citrate)</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs</entry>
                  <entry>Serum, plasma (no citrate)</entry>
                  <entry>Qualitative or quantitative (≥12 mIU/ml immune; range, 4.23 to &gt;1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
                <row>
                  <entry>Prism</entry>
                  <entry>CLIA</entry>
                  <entry>HBsAg</entry>
                  <entry>Serum, plasma</entry>
                  <entry>Qualitative</entry>
                  <entry>C</entry>
                </row>
                <row>
                  <entry>Anti-HBc total</entry>
                  <entry>Serum, plasma (no heparin)</entry>
                  <entry>Qualitative</entry>
                  <entry>C</entry>
                </row>
                <row>
                  <entry>Bio-Rad Laboratories</entry>
                  <entry>Genetic Systems</entry>
                  <entry>EIA</entry>
                  <entry>HBsAg 3.0</entry>
                  <entry>Serum, plasma, and cadaveric serum</entry>
                  <entry>Qualitative</entry>
                  <entry>B</entry>
                </row>
                <row>
                  <entry>Monolisa</entry>
                  <entry>EIA</entry>
                  <entry>Anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs PLUS</entry>
                  <entry>Serum, plasma (citrate may give lower values)</entry>
                  <entry>Qualitative or quantitative (≥10 mIU/ml immune; range, 2 to 1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
                <row>
                  <entry>DiaSorin</entry>
                  <entry><para id="ch0131s0000p0041">ETI</para>
                    <para id="ch0131s0000p0043">Liaison</para>
                  </entry>
                  <entry><para id="ch0131s0000p0044">EIA</para>
                    <para id="ch0131s0000p0046">CLIA</para>
                  </entry>
                  <entry>HBsAg, anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>HBeAg, anti-HBe</entry>
                  <entry>Serum, plasma</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry><para id="ch0131s0000p0047">Anti-HBs</para>
                    <para id="ch0131s0000p0048">HBsAg, Anti-HBc total, anti-HBc IgM</para>
                    <para id="ch0131s0000p0049">HBeAg, anti-HBe</para>
                    <para id="ch0131s0000p0050">Anti-HBs</para>
                  </entry>
                  <entry><para id="ch0131s0000p0051">Serum, plasma</para>
                    <para id="ch0131s0000p0052">Serum, plasma</para>
                    <para id="ch0131s0000p0053">Serum, plasma</para>
                    <para id="ch0131s0000p0054">Serum, plasma (EDTA only)</para>
                  </entry>
                  <entry><para id="ch0131s0000p0055">Qualitative</para>
                    <para id="ch0131s0000p0056">Qualitative</para>
                    <para id="ch0131s0000p0057">Qualitative or quantitative (≥10 mIU/ml positive; range, 3 to 500 mIU/ml)</para>
                  </entry>
                  <entry><para id="ch0131s0000p0058">A, D</para>
                    <para id="ch0131s0000p0059">A</para>
                    <para id="ch0131s0000p0060">A</para>
                    <para id="ch0131s0000p0061">A, D</para>
                  </entry>
                </row>
                <row>
                  <entry>Ortho Clinical Diagnostics</entry>
                  <entry>Vitros</entry>
                  <entry>CLIA</entry>
                  <entry>HBsAg, anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma (heparin and/or citrate can lower sample/cutoff ratio in some HBsAg or anti-HBc IgM reactive samples)</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>HBeAg, anti-HBe</entry>
                  <entry>Serum</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs</entry>
                  <entry>Serum</entry>
                  <entry>Qualitative or quantitative (≥12 mIU/ml positive; range, 4.23 to 1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
                <row>
                  <entry>Roche Diagnostics</entry>
                  <entry>Elecsys</entry>
                  <entry>ECLIA</entry>
                  <entry>HBsAg II<superscript><link linkend="ch0131s0000a0058"><emphasis>g</emphasis></link></superscript><anchor id="ch0131s0000a0051"/>, anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>HBeAg, anti- HBe</entry>
                  <entry>Serum, plasma</entry>
                  <entry></entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs II</entry>
                  <entry>Serum, plasma (EDTA only)</entry>
                  <entry>Qualitative or quantitative (≥10 mIU/ml positive; range, 3.5 to 1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
                <row>
                  <entry>Siemens Healthcare Diagnostics</entry>
                  <entry>Advia Centaur</entry>
                  <entry>CLIA</entry>
                  <entry><para id="ch0131s0000p0062">HBsAg, HBsAg II<superscript><link linkend="ch0131s0000a0058"><emphasis>g</emphasis></link></superscript></para>
                    <para id="ch0131s0000p0063">Anti-HBc total, anti-HBc IgM</para>
                  </entry>
                  <entry>Serum, plasma (no citrate, except for HBsAg II)</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>HBeAg, anti-HBe 1, anti-HBe 2</entry>
                  <entry>Serum, plasma (no citrate)</entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs 2</entry>
                  <entry>Serum, plasma (no citrate)</entry>
                  <entry>Qualitative or quantitative (≥12 mIU/ml immune; range, 3.1 to 1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
                <row>
                  <entry>Immulite</entry>
                  <entry>CLIA</entry>
                  <entry>HBsAg, anti-HBc total, anti-HBc IgM</entry>
                  <entry>Serum, plasma<superscript><link linkend="ch0131s0000a0056"><emphasis>e</emphasis></link></superscript></entry>
                  <entry>Qualitative</entry>
                  <entry>A</entry>
                </row>
                <row>
                  <entry>Anti-HBs</entry>
                  <entry>Serum, plasma (heparin only)</entry>
                  <entry>Qualitative or quantitative (≥12 mIU/ml immune; range, 3.0 to 1,000 mIU/ml)</entry>
                  <entry>A, D</entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para id="ch0131s0000p0064" role="table-footnote"><superscript><link linkend="ch0131s0000a0045"><emphasis>a</emphasis></link></superscript><anchor id="ch0131s0000a0052"/>CLIA, chemiluminescent immunoassay; EIA, enzyme immunoassay; ECLIA, electrochemiluminescence.</para>
          <para id="ch0131s0000p0065" role="table-footnote"><superscript><link linkend="ch0131s0000a0046"><emphasis>b</emphasis></link></superscript><anchor id="ch0131s0000a0053"/>Serum includes specimens collected in serum separator tubes; plasma includes collections in potassium EDTA, sodium citrate, sodium heparin, lithium heparin, and/or plasma separator tubes unless otherwise stated for a specific test.</para>
          <para id="ch0131s0000p0066" role="table-footnote"><superscript><link linkend="ch0131s0000a0047"><emphasis>c</emphasis></link></superscript><anchor id="ch0131s0000a0054"/>All information on methods is derived from FDA submissions and manufacturers’ information when available.</para>
          <para id="ch0131s0000p0067" role="table-footnote"><superscript><link linkend="ch0131s0000a0048"><emphasis>d</emphasis></link></superscript><anchor id="ch0131s0000a0055"/>All samples with reactive and/or gray zone/indeterminate results are retested in duplicate before reporting results. See package insert for specific instructions.</para>
          <para id="ch0131s0000p0068" role="table-footnote"><superscript><link linkend="ch0131s0000a0049"><emphasis>e</emphasis></link></superscript><anchor id="ch0131s0000a0056"/>A, diagnostic use only, not for use in evaluation of blood, blood products, or tissue or blood donors; B, diagnostic use and screening of blood, blood products, and/or tissue or blood donors; C, screening of blood, blood products, and/or tissue or blood donors only; D, evaluation of postvaccination response.</para>
          <para id="ch0131s0000p0069" role="table-footnote"><superscript><link linkend="ch0131s0000a0050"><emphasis>f</emphasis></link></superscript><anchor id="ch0131s0000a0057"/>All assays require positive HBsAg results to be repeated and confirmed with a separate confirmation assay specific for each kit.</para>
          <para id="ch0131s0000p0070" role="table-footnote"><superscript><link linkend="ch0131s0000a0051"><emphasis>g</emphasis></link></superscript><anchor id="ch0131s0000a0058"/>Detects HBsAg wild type and escape mutants.</para>
          <para id="ch0131s0000p0071">The major antigenic determinant on the HBsAg is designated the “a” determinant. This antigenic site is formed by a conformational structure containing a disulfide bond that results in a specific three-dimensional epitope. The region between amino acids 124 and 147 is found within the major hydrophilic loop of the protein (17, 78–80). There is a concern that current diagnostic assays do not detect HBsAg with alterations within this major antigenic epitope, since some HBsAg assays use monoclonal antibodies that capture the HBsAg using this immunodominant epitope. These HBV strains are known as “escape mutants.” The first escape mutant that was described occurred in a child born to an HBV-positive mother who transmitted HBV to the child despite vaccination and HBIG (<link linkend="ch0131s0000li0072">72</link>). This virus had a substitution of arginine for glycine in HBsAg at amino acid position 145. A single amino acid change altered the antigenic portion of the protein such that vaccine-induced antibody no longer recognized the antigen. This allowed the altered virus to persist in the infant. Subsequently, the patient remained positive for HBV DNA and HBsAg (with mutation) for longer than 12 years. Since that time, a number of other substitution mutants within the “a” determinant region of HBsAg have been recognized. Recent studies have evaluated HBsAg assays to determine their ability to detect well-defined HBsAg mutants and have found that some mutations in the HBsAg may be missed by diagnostic assays (<link linkend="ch0131s0000li0072">72</link>, <link linkend="ch0131s0000li0077">77</link>, <link linkend="ch0131s0000li0078">78</link>). Many assays have been updated to better detect mutants (e.g., HBsAg II [<link linkend="ch0131s0000a0044">Table 2</link>]) (<link linkend="ch0131s0000li0018">18</link>). Nevertheless, the CDC recently reported a hemodialysis patient who was HBsAg negative as determined by several commercial assays yet had an HBV DNA level of 14,200,000 IU/ml (<link linkend="ch0131s0000li0081">81</link>).</para>
          <anchor id="ch0131s0000a0059"/>
          <beginpage pagenum="2171"/>
          <para id="ch0131s0000p0072">Although very effective, EIA- or CLIA-based HBsAg tests require high-quality laboratories with expensive equipment, cold storage of reagents, well-trained personnel, and constant electricity supply, which are often scarce in HBV-endemic areas. The WHO Blood and Clinical Safety and Clinical Technology Department initiated a program to encourage the development of the HBsAg point-of-care (POC) tests (<ulink url="https://www.ncbi.nlm.nih.gov/books/NBK442272/">https://www.ncbi.nlm.nih.gov/books/NBK442272/</ulink>, accessed 17 January 2022). As a result, POC diagnostic tests for HBsAg have become the first-line test for the diagnosis of chronic HBV infection in resource-limited settings (<link linkend="ch0131s0000li0082">82</link>). A systematic review and meta-analysis of 27 studies showed that the Determine HBsAg POC kit (Alere Medical Co., Ltd., Chiba, Japan [now Abbott]) has very high sensitivity (96.7%, confidence interval [CI] 95.1 to 99.2%) and specificity (99.6%, CI 97.0 to 99.9%) in developing countries (<link linkend="ch0131s0000li0073">73</link>). The second edition of the Determine HBsAg assay is now commercially available (<link linkend="ch0131s0000li0083">83</link>).</para>
          <para id="ch0131s0000p0073">In response to the concern that blood donors with an HBsAg mutant may not be identified by HBV antigen assays, most countries screen blood donors for anti-HBc in addition to screening for HBsAg. Many countries also screen blood donations for HBV DNA (<link linkend="ch0131s0000li0078">78</link>, <link linkend="ch0131s0000li0084">84</link>). Individuals with positive tests for HBV DNA and anti-HBc and/or patients with positive results for HBeAg and/or HBV DNA but negative for HBsAg could be infected with an escape mutant (<link linkend="ch0131s0000li0079">79</link>).</para>
          <para id="ch0131s0000p0074">Serum HBsAg quantification has been recently reported as a useful marker to predict disease activity and monitor treatment response in chronic hepatitis B and is widely used in Europe and Asia but not yet in the United States (<link linkend="ch0131s0000li0017">17</link>, <link linkend="ch0131s0000li0018">18</link>). The HBsAg level is considered a surrogate for transcriptional activity of cccDNA, independent of HBV DNA replication and viral load. It can assist in the differentiation of immune tolerance and immune clearance in HBeAg-positive patients, predict inactive disease and spontaneous HBsAg seroclearance in HBeAg-negative patients, and identify HBV-positive mothers at highest risk for maternofetal transmission (<link linkend="ch0131s0000li0085">85</link>–<link linkend="ch0131s0000li0087">87</link>). It is not useful for identifying HBeAg-negative patients with significant fibrosis (<link linkend="ch0131s0000li0088">88</link>). The determination of HBsAg level is pivotal to individualize pegylated interferon treatment (<link linkend="ch0131s0000li0017">17</link>, <link linkend="ch0131s0000li0033">33</link>). Quantification of HBsAg q(HBsAg) is not currently recommended as a predictor of treatment success with nucleoside analogues (<link linkend="ch0131s0000li0071">71</link>). Due to the development of new antiviral treatments aiming at HBsAg seroclearance as a functional cure, HBsAg quantification in serum may become a mandatory measurement. The third international standard for HBsAg is available from the WHO (<link linkend="ch0131s0000li0089">89</link>, <link linkend="ch0131s0000li0090">90</link>). Devices that measure HBsAg levels in IU/milliliter include the Abbott Architect HBsAg, DiaSorin LiaisonXL Murex HBsAg Quant, and Roche Elecsys HBsAg II. A head-to-head comparison of these three assays indicated a good correlation between them but clearly showed an influence of both the genotype and the presence of “a” determinant variants in HBsAg quantification (<link linkend="ch0131s0000li0018">18</link>). Quantitative commercial assays are available in Europe but are not yet FDA approved in the United States. However, at the time of this writing, Quest Diagnostics and LabCorp reference laboratories offer a quantitative HBsAg assay. Recent studies have shown that the persistent loss of HBsAg is a primary measure of therapeutic success (<link linkend="ch0131s0000li0017">17</link>).</para>
        </sect3>
        <sect3 id="ch0131s0007s0002">
          <title>HBeAg</title>
          <anchor id="ch0131s0007a0005"/>
          <anchor id="ch0131s0000a0060"/>
          <para id="ch0131s0000p0075">The detection of HBeAg in serum is a sign of rapid viral replication usually associated with high HBV DNA levels. HBeAg-positive patients are highly infectious. However, some HBV strains do not make HBeAg due to a precore mutation. Patients infected with these mutant strains may have high HBV DNA levels in the absence of detectable HBeAg (<link linkend="ch0131s0000li0079">79</link>). Several commercial assays are available for the detection of HBeAg in serum or plasma, though sensitivity can vary significantly by assay (<link linkend="ch0131s0000li0091">91</link>). HBeAg-positive samples should be HBsAg and HBV DNA positive. If not, the result should be questioned and investigated further to ensure validity prior to reporting (<link linkend="ch0131s0000a0044">Table 2</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0131s0007s0003">
        <title>Nucleic Acid Detection</title>
        <anchor id="ch0131s0007a0006"/>
        <anchor id="ch0131s0000a0061"/>
        <para id="ch0131s0000p0076">Molecular assays to quantitate HBV DNA are used for the initial evaluation of HBV infections and the monitoring of patients with chronic infections during treatment (<link linkend="ch0131s0000li0092">92</link>, <link linkend="ch0131s0000li0093">93</link>). In addition, as mentioned above, blood donors are routinely screened for HBV DNA using qualitative tests to identify donors in the early stage of HBV infection.</para>
        <para id="ch0131s0000p0077">A number of quantitative assays, most using real-time PCR, have been developed to detect and monitor HBV DNA levels in infected patients (80, 94–99). A transcription-mediated amplification assay is also FDA approved and shows strong correlation to FDA-approved PCR assays (<link linkend="ch0131s0000li0100">100</link>, <link linkend="ch0131s0000li0101">101</link>). In addition, loop-mediated isothermal amplification has been reported as a rapid and sensitive qualitative test option for use in resource-limited areas (<link linkend="ch0131s0000li0102">102</link>, <link linkend="ch0131s0000li0103">103</link>). Monitoring of HBV DNA levels provides information on the effectiveness of antiviral treatment and can indicate when a change in the antiviral regimen is needed. Most of the available assays have a lower limit of detection, between 3 and 30 IU/ml, and can quantify levels up to 1 billion IU/ml. This wide range of quantitation allows for monitoring HBV DNA early after infection and identifying HBV infections resistant to antiviral therapy (<anchor id="ch0131s0000a0062"/><link linkend="ch0131s0000a0064">Table 3</link>) (<link linkend="ch0131s0000li0095">95</link>). A high level of HBV DNA following resolution of clinical hepatitis indicates a failure to control viral replication (<link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0093">93</link>).</para>
        <anchor id="ch0131s0000a0063"/>
        <beginpage pagenum="2172"/>
        <table id="ch0131s0000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0131s0000a0064"/><link linkend="ch0131s0000a0062">TABLE 3</link></phrase></emphasis> Molecular assays used to detect HBV nucleic acid
</title>
          
          <tgroup cols="8">
            <tbody>
              <row>
                <entry>Manufacturer</entry>
                <entry><phrase role="center">Assay</phrase>
                </entry>
                <entry><phrase role="center">Method</phrase>
                </entry>
                <entry><phrase role="center">Platform</phrase>
                </entry>
                <entry><phrase role="center">Specimens</phrase>
                </entry>
                <entry><phrase role="center">Quantitative range</phrase>
                </entry>
                <entry><phrase role="center">Sensitivity<superscript><link linkend="ch0131s0000a0068"><emphasis>a</emphasis></link></superscript></phrase>
                  <anchor id="ch0131s0000a0065"/>
                </entry>
                <entry><phrase role="center">Approved uses<superscript><link linkend="ch0131s0000a0069"><emphasis>b</emphasis></link></superscript></phrase>
                  <anchor id="ch0131s0000a0066"/>
                </entry>
              </row>
              <row>
                <entry>Abbott Molecular</entry>
                <entry><para id="ch0131s0000p0078">Abbott RealTime HBV</para>
                  <para id="ch0131s0000p0079">Alinity m HBV</para>
                </entry>
                <entry><para id="ch0131s0000p0080">Real-time PCR</para>
                  <para id="ch0131s0000p0081">Real-time PCR</para>
                </entry>
                <entry><para id="ch0131s0000p0082">M2000</para>
                  <para id="ch0131s0000p0083">Alinity m System</para>
                </entry>
                <entry><para id="ch0131s0000p0084">Serum, plasma (EDTA)</para>
                  <para id="ch0131s0000p0085">Serum, plasma (EDTA, ACD)</para>
                </entry>
                <entry><para id="ch0131s0000p0086">10–10<superscript>9</superscript> IU/ml</para>
                  <para id="ch0131s0000p0087">10–10<superscript>9</superscript> IU/ml</para>
                </entry>
                <entry><para id="ch0131s0000p0088">6.4 IU/ml for plasma;</para>
                  <para id="ch0131s0000p0089">3.82 IU/ml for serum</para>
                  <para id="ch0131s0000p0090">10 IU/ml</para>
                </entry>
                <entry><para id="ch0131s0000p0091"><phrase role="center">A</phrase>
                  </para>
                  <para id="ch0131s0000p0092"><phrase role="center">A</phrase>
                  </para>
                </entry>
              </row>
              <row>
                <entry>Hologic</entry>
                <entry>Aptima HBV Quant</entry>
                <entry>TMA</entry>
                <entry>Panther system</entry>
                <entry>Serum, plasma (EDTA, ACD)</entry>
                <entry>10–10<superscript>9</superscript> IU/ml</entry>
                <entry><para id="ch0131s0000p0093">4.8 IU/ml for plasma;</para>
                  <para id="ch0131s0000p0094">5.9 IU/ml for serum</para>
                </entry>
                <entry><phrase role="center">A</phrase>
                </entry>
              </row>
              <row>
                <entry>Qiagen</entry>
                <entry><emphasis>artus</emphasis> HBV PCR</entry>
                <entry>Real-time PCR</entry>
                <entry>Roto-Gene</entry>
                <entry>Plasma (EDTA, ACD)</entry>
                <entry>10–10<superscript>9</superscript> IU/ml</entry>
                <entry>3.8 IU/ml</entry>
                <entry><phrase role="center">A</phrase>
                </entry>
              </row>
              <row>
                <entry>Lightcycler</entry>
                <entry>10–10<superscript>10</superscript> IU/ml</entry>
                <entry>5.8 IU/ml</entry>
                <entry><phrase role="center">A</phrase>
                </entry>
              </row>
              <row>
                <entry>Roche Molecular Systems</entry>
                <entry>cobas AmpliPrep/cobas TaqMan v.2.0</entry>
                <entry>Real-time PCR</entry>
                <entry>Ampliprep/TaqMan Analyzer</entry>
                <entry>Serum, plasma (EDTA)</entry>
                <entry>20–1.7 × 10<superscript>8</superscript> IU/ml</entry>
                <entry>20 IU/ml</entry>
                <entry><phrase role="center">A</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas HBV</entry>
                <entry>Real-time PCR</entry>
                <entry><para id="ch0131s0000p0095">cobas 4800</para>
                  <para id="ch0131s0000p0096">cobas 6800/8800</para>
                </entry>
                <entry>Serum, plasma (EDTA)</entry>
                <entry>10–10<superscript>9</superscript> IU/ml</entry>
                <entry>2.4 serum–2.7 plasma IU/ml; lower if sample input is &lt;0.5 ml</entry>
                <entry><phrase role="center">A</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas AmpliScreen HBV</entry>
                <entry>PCR followed by hybridization</entry>
                <entry>cobas Amplicor Analyzer</entry>
                <entry>Serum, plasma (EDTA, ACD), cadaveric serum or plasma</entry>
                <entry>Qualitative</entry>
                <entry><para id="ch0131s0000p0097">4.41 (multiprep);</para>
                  <para id="ch0131s0000p0098">15.99 (standard prep) IU/ml</para>
                </entry>
                <entry><phrase role="center">B</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas TaqScreen MPX</entry>
                <entry>Real-time PCR (multiplex)</entry>
                <entry>cobas 6800/8800</entry>
                <entry>Qualitative</entry>
                <entry>1.3–1.4 IU/ml</entry>
                <entry><phrase role="center">B</phrase>
                </entry>
              </row>
              <row>
                <entry>Grifols USA</entry>
                <entry>Procleix Ultrio</entry>
                <entry>TMA<superscript><link linkend="ch0131s0000a0070"><emphasis>c</emphasis></link></superscript><anchor id="ch0131s0000a0067"/> (multiplex)</entry>
                <entry>Tigris</entry>
                <entry></entry>
                <entry>Qualitative</entry>
                <entry>8.5 IU/ml</entry>
                <entry><phrase role="center">B</phrase>
                </entry>
              </row>
              <row>
                <entry></entry>
                <entry>Procleix Ultrio Plus</entry>
                <entry>TMA (multiplex)</entry>
                <entry>Tigris</entry>
                <entry></entry>
                <entry>Qualitative</entry>
                <entry>4.1 IU/ml</entry>
                <entry><phrase role="center">B</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0131s0000p0099" role="table-footnote"><superscript><link linkend="ch0131s0000a0065"><emphasis>a</emphasis></link></superscript><anchor id="ch0131s0000a0068"/>All assays claim to detect genotypes A to H; Qiagen and Roche assays claim ability to detect precore mutations.</para>
        <para id="ch0131s0000p0100" role="table-footnote"><superscript><link linkend="ch0131s0000a0066"><emphasis>b</emphasis></link></superscript><anchor id="ch0131s0000a0069"/>A, Monitor response to antiviral therapy; B, screen donor blood or blood products for presence of HBV DNA.</para>
        <para id="ch0131s0000p0101" role="table-footnote"><superscript><link linkend="ch0131s0000a0067"><emphasis>c</emphasis></link></superscript><anchor id="ch0131s0000a0070"/>TMA, transcription mediated amplification.</para>
        <para id="ch0131s0000p0102">Commercially available HBV DNA assays differ in their limits of detection, dynamic ranges, and methods used to measure DNA levels (<link linkend="ch0131s0000a0064">Table 3</link>). An international HBV DNA standard was established in 2001 by the WHO in response to the need to standardize HBV DNA quantification (<link linkend="ch0131s0000li0062">62</link>, <link linkend="ch0131s0000li0104">104</link>). The current fourth WHO standard virus preparation is a high-titer genotype A2 preparation (code 10/266) which has been assigned a potency of 10<superscript>5.98</superscript> IU/ml when constituted in 0.5 ml of nuclease-free water (<link linkend="ch0131s0000li0105">105</link>). The WHO standard has allowed results for different HBV DNA assays to be reported in IU per milliliter. However, despite the availability of this standard, the various quantitative assays usually have different IU-to-copy number conversion factors, demonstrating their variability. Thus, the best practice is the consistent monitoring of patients using the same manufacturer’s assay in the same laboratory (<link linkend="ch0131s0000li0092">92</link>, <link linkend="ch0131s0000li0093">93</link>, <link linkend="ch0131s0000li0095">95</link>).</para>
        <para id="ch0131s0000p0103">Some of the variability of HBV DNA quantification may occur during collection and processing of the specimen. Most assays use serum or plasma (EDTA or ACD) as the specimen of choice. In general, the tube should be centrifuged and the serum or plasma should be separated from the cells within 6 to 24 h after collection, as specified in the package insert for the kit employed. The manufacturer’s instructions should be followed for approved specimen types and collection tubes, as well as processing and storage conditions and temperature. Repeated freezing and thawing should be avoided because this may reduce assay sensitivity.</para>
        <para id="ch0131s0000p0104">Most commercial assays quantitate HBV DNA and cover an 8- to 9-log<subscript>10</subscript> range, which permits the accurate evaluation of HBV levels above a million down to very low levels that occur during treatment or in inactive carriers. Several studies have shown that a reduction of 2 log<subscript>10</subscript> in HBV DNA levels in the first 6 months of antiviral therapy indicates treatment efficacy (<link linkend="ch0131s0000li0062">62</link>, <link linkend="ch0131s0000li0081">81</link>, <link linkend="ch0131s0000li0089">89</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0131s0008">
      <title>Identification</title>
      <anchor id="ch0131s0008a0001"/>
      <anchor id="ch0131s0000a0071"/>
      <para id="ch0131s0000p0105">The methods for identification of HBV infection use a combination of molecular, antigenic, and serologic methods described in “Direct Detection” above and “Serologic Tests” below.</para>
    </sect1>
    <sect1 id="ch0131s0009">
      <title>Typing Systems</title>
      <anchor id="ch0131s0009a0001"/>
      <anchor id="ch0131s0000a0072"/>
      <para id="ch0131s0000p0106">Antigenic variation occurs naturally in HBV due to genetic heterogeneity. These various genetic differences are used to classify HBV into 10 distinct genotypes, with over 40 subgenotypes (<link linkend="ch0131s0000li0106">106</link>, <link linkend="ch0131s0000li0107">107</link>). Genotypes A through J are presented in <anchor id="ch0131s0000a0073"/><link linkend="ch0131s0000a0075">Table 4</link>. HBV genotypes are distinguished by a genetic divergence of 8% or more within the complete nucleotide sequence (<link linkend="ch0131s0000li0002">2</link>, <link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0032">32</link>). There are substantial data that have correlated HBV genotypes with disease outcome (<link linkend="ch0131s0000li0033">33</link>, <link linkend="ch0131s0000li0108">108</link>, <link linkend="ch0131s0000li0109">109</link>). The most common genotypes associated with chronic HBV infections are B and C. Patients with genotype B are more likely to spontaneously convert to anti-HBeAg and thus have less severe liver damage. Genotype C is more common in Asia and has been associated with a high risk of progression to cirrhosis (<link linkend="ch0131s0000a0034">Fig. 3B</link>). However, in European studies, genotype D has been shown to be more likely to be associated with active liver disease than other genotypes and is more likely to harbor precore mutations (<link linkend="ch0131s0000li0079">79</link>, <link linkend="ch0131s0000li0108">108</link>, <link linkend="ch0131s0000li0109">109</link>). It is noted that most of these patients acquired these infections in childhood and had more exposure to HBV than other patients evaluated. It is not clear yet how the variances in HBV genotypes affect clinical outcomes. It is possible that the differences are associated with the viral expression of immune epitopes or the loss of critical control over viral replication such as precore and core promoter mutations. Thus, in spite of the intriguing studies of HBV genotypes, the role of HBV genotyping in predicting clinical and therapeutic outcomes has not been firmly established. However, with additional studies, the value of HBV genotyping to determine specific treatment will likely become apparent (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0027">27</link>, <link linkend="ch0131s0000li0049">49</link>).</para>
      <anchor id="ch0131s0000a0074"/>
      <beginpage pagenum="2173"/>
      <table id="ch0131s0000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0131s0000a0075"/><link linkend="ch0131s0000a0073">TABLE 4</link></phrase></emphasis> HBV genotypes and major geographic circulation
</title>
        
        <tgroup cols="5">
          <tbody>
            <row>
              <entry><phrase role="center">Genotype<superscript><emphasis>a</emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Subtypes and serotypes</phrase>
              </entry>
              <entry><phrase role="center">Genome size (nucleotides)</phrase>
              </entry>
              <entry><phrase role="center">Geographic connection</phrase>
              </entry>
              <entry><phrase role="center">Disease relationship</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">A</phrase>
              </entry>
              <entry>Subtypes A1–A3; serotypes adw2, ayw1</entry>
              <entry><phrase role="center">3,221</phrase>
              </entry>
              <entry>Northwestern Europe, Spain, Poland, USA, Central Africa, India, Brazil</entry>
              <entry>HCC and cirrhosis in older patients; core promoter mutations (A1762T, G1764A) detected</entry>
            </row>
            <row>
              <entry><phrase role="center">B</phrase>
              </entry>
              <entry>Subtypes B1–B6; serotypes adw2, ayw1</entry>
              <entry><phrase role="center">3,215</phrase>
              </entry>
              <entry>Southeast Asia, Taiwan, Japan, Indonesia, China, Australia</entry>
              <entry>HCC and cirrhosis in both younger and older patients; precore mutations (G1896A) detected</entry>
            </row>
            <row>
              <entry><phrase role="center">C</phrase>
              </entry>
              <entry>Subtypes C1–C4; serotypes adw2, adrq+, adrq−, ayr</entry>
              <entry><phrase role="center">3,215</phrase>
              </entry>
              <entry>Asia, Indonesia, India, Australia, USA, Brazil</entry>
              <entry>Higher risk of HCC and cirrhosis than with genotype B; precore mutations (G1896A) and core promoter mutations (A1762T, G1764A) detected</entry>
            </row>
            <row>
              <entry><phrase role="center">D</phrase>
              </entry>
              <entry>Subtypes D1–D4; serotypes ayw2, ayw3</entry>
              <entry><phrase role="center">3,182</phrase>
              </entry>
              <entry>Mediterranean area, Middle East, India, Spain, USA, Brazil (generally found worldwide)</entry>
              <entry>Chronic HBV, cirrhosis in older patients; precore mutations (G1896A) and core promoter mutations (A1762T, G1764A) detected</entry>
            </row>
            <row>
              <entry><phrase role="center">E</phrase>
              </entry>
              <entry>Subtypes unknown; serotype ayw4</entry>
              <entry><phrase role="center">3,212</phrase>
              </entry>
              <entry>West Africa</entry>
              <entry>Unknown</entry>
            </row>
            <row>
              <entry><phrase role="center">F</phrase>
              </entry>
              <entry>Subtypes D1–D4; serotypes adw4q−, adw2, ayw4</entry>
              <entry><phrase role="center">3,215</phrase>
              </entry>
              <entry>Central and South America, Bolivia, Venezuela, Polynesia, Alaska</entry>
              <entry>HCC in young children and adults</entry>
            </row>
            <row>
              <entry><phrase role="center">G</phrase>
              </entry>
              <entry>Subtypes unknown; serotype adw2</entry>
              <entry><phrase role="center">3,248</phrase>
              </entry>
              <entry>Australia, France, Germany, USA</entry>
              <entry>Almost always is a coinfection with other HBV types</entry>
            </row>
            <row>
              <entry><phrase role="center">H</phrase>
              </entry>
              <entry>Subtypes unknown; serotype adw4</entry>
              <entry><phrase role="center">3,215</phrase>
              </entry>
              <entry>Central and South America, USA</entry>
              <entry>Unknown</entry>
            </row>
            <row>
              <entry><phrase role="center">I</phrase>
              </entry>
              <entry>Subtypes I1-I2; serotype adw2, ayw2</entry>
              <entry><phrase role="center">3,215</phrase>
              </entry>
              <entry>Southeast Asia</entry>
              <entry>Unknown</entry>
            </row>
            <row>
              <entry><phrase role="center">J</phrase>
              </entry>
              <entry>Subtypes unknown; serotype ayw3</entry>
              <entry><phrase role="center">3,182</phrase>
              </entry>
              <entry>Japan</entry>
              <entry>Unknown</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
    </sect1>
    <sect1 id="ch0131s0010">
      <title>Serologic Tests</title>
      <anchor id="ch0131s0010a0001"/>
      <anchor id="ch0131s0000a0076"/>
      <para id="ch0131s0000p0107">Serologic tests for HBV-specific antibodies are used to determine the stage of HBV disease and to establish immunity after HBV vaccination. As the host mounts an immune response, the first antibodies to appear are IgM specific for HBc (IgM anti-HBc); this is followed by the appearance of total anti-HBc, anti-HBe, and finally anti-HBs (<link linkend="ch0131s0000li0110">110</link>) (<anchor id="ch0131s0000a0077"/><link linkend="ch0131s0000a0087">Fig. 4</link>). A number of commercial assays are available for HBV serologic testing (<link linkend="ch0131s0000a0044">Table 2</link>).</para>
      <sect2 id="ch0131s0010s0001">
        <title>IgM Anti-HBc</title>
        <anchor id="ch0131s0010a0002"/>
        <anchor id="ch0131s0000a0078"/>
        <para id="ch0131s0000p0108">IgM anti-HBc persists for several weeks to months after an initial infection. The detection of IgM anti-HBc indicates an infection of less than 6 months’ duration (<link linkend="ch0131s0000a0013">Table 1</link>). During this stage of disease, the patient’s liver enzymes may be elevated. A negative IgM anti-HBc result excludes a recent, acute infection but does not rule out chronic infection (<link linkend="ch0131s0000li0092">92</link>, <link linkend="ch0131s0000li0093">93</link>, <link linkend="ch0131s0000li0111">111</link>). The presence of IgM anti-HBc identifies patients who are acutely infected; such patients often have high levels of HBV DNA (<link linkend="ch0131s0000li0111">111</link>). Less commonly, IgM anti-HBc may be detected during severe acute exacerbations of chronic hepatitis B (<link linkend="ch0131s0000li0112">112</link>). IgM anti-HBc and, therefore, total anti-HBc are also the only serologic markers that are positive during the seronegative window of acute HBV, when HBsAg has declined to an undetectable level but before anti-HBs appears. During this period, HBsAg is bound in immune complexes to anti-HBs, thus rendering both undetectable by immunoassay.</para>
      </sect2>
      <sect2 id="ch0131s0010s0002">
        <title>Total Anti-HBc</title>
        <anchor id="ch0131s0010a0003"/>
        <anchor id="ch0131s0000a0079"/>
        <para id="ch0131s0000p0109">A negative anti-HBc test indicates that a person does not have a history of infection with HBV. A positive total anti-HBc result can indicate an acute infection, in which the patient is also HBsAg positive and IgM anti-HBc positive; a resolved (HBsAg-negative) infection; or a chronic (HBsAg-positive) HBV infection (<link linkend="ch0131s0000a0013">Table 1</link>) (<link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0111">111</link>, <link linkend="ch0131s0000li0113">113</link>). Total anti-HBc antibodies remain after IgM anti-HBc disappears and can be detected for many years. These antibodies persist longer than anti-HBs. Thus, total anti-HBc is the best marker for documenting prior exposure to HBV infection. Vaccines do not include HBcAg; thus, vaccination induces only anti-HBs. Therefore, anti-HBc is not present in vaccinated individuals unless they were infected with HBV prior to vaccination (<link linkend="ch0131s0000li0114">114</link>). Individuals positive for anti-HBc without any other serologic evidence of HBV infection (i.e., isolated anti-HBc) should be considered as exposed to HBV (<link linkend="ch0131s0000li0111">111</link>). This serologic pattern is consistent with a remote, past HBV infection that has resolved or with an occult HBV infection with very low viral DNA levels (<link linkend="ch0131s0000li0019">19</link>, <link linkend="ch0131s0000li0113">113</link>). Thus, HBV DNA testing should be performed in all patients with isolated anti-HBc (<link linkend="ch0131s0000li0036">36</link>). Many patients with isolated anti-HBc may be coinfected with hepatitis C virus and/or human immunodeficiency virus (HIV) (<link linkend="ch0131s0000li0115">115</link>). Rarely, isolated anti-HBc could be a nonspecific result.</para>
        <para id="ch0131s0000p0110">Commercial kits for detection of total anti-HBc are available and use a variety of methods and instrumentation (<link linkend="ch0131s0000a0044">Table 2</link>). All assays use recombinant HBc antigen for capture of antibody.</para>
        <anchor id="ch0131s0000a0080"/>
        <beginpage pagenum="2174"/>
      </sect2>
      <sect2 id="ch0131s0010s0003">
        <title>Anti-HBs</title>
        <anchor id="ch0131s0010a0004"/>
        <anchor id="ch0131s0000a0081"/>
        <para id="ch0131s0000p0111">A negative result for anti-HBs in the absence of any other HBV-specific antigen or antibody indicates that a person has not been infected with HBV and has not been vaccinated with HBV. A positive result is consistent with immunity to HBV due to an infection or from effective vaccination (<link linkend="ch0131s0000a0013">Table 1</link>). Anti-HBs quantitation panels are commercially available and should be used when validating anti-HBs assays.</para>
        <para id="ch0131s0000p0112">Anti-HBs is a key serologic marker for both vaccine-induced immunity and immunity due to infection. As HBV vaccination has become more widespread, this serologic marker is used to monitor vaccine success. Both the WHO and CDC recognize a level of &gt;10 mIU/ml of anti-HBs as an indication of protective immunity. However, it has been demonstrated that levels of anti-HBs determined by one commercial assay system cannot be compared with those detected with a different system despite the use of international standards (<link linkend="ch0131s0000li0116">116</link>, <link linkend="ch0131s0000li0117">117</link>). Thus, levels designated positive by different test kits may vary (<link linkend="ch0131s0000a0044">Table 2</link>).</para>
        <para id="ch0131s0000p0113">Postvaccination testing for the presence of anti-HBs is not recommended for infants, children, or most adults. The CDC lists exceptions to this rule, including infants born to mothers who are HBsAg positive, immunocompromised patients, dialysis patients, and sexual partners of people who are HBV positive, and to confirm successful vaccination in health care workers to prevent the transmission of HBV in the health care setting (<link linkend="ch0131s0000li0118">118</link>).</para>
        <para id="ch0131s0000p0114">HBV escape mutants in which the HBsAg has mutated can result in HBV infections despite vaccine-induced anti-HBs antibody (<link linkend="ch0131s0000li0079">79</link>). In these situations, both HBsAg and anti-HBs may be detected simultaneously in the patient’s blood (<link linkend="ch0131s0000li0081">81</link>, <link linkend="ch0131s0000li0119">119</link>).</para>
      </sect2>
      <sect2 id="ch0131s0010s0004">
        <title>Anti-HBe</title>
        <anchor id="ch0131s0010a0005"/>
        <anchor id="ch0131s0000a0082"/>
        <para id="ch0131s0000p0115">A positive test for anti-HBe is associated with a decrease in viral replication and thus viral titer (<link linkend="ch0131s0000a0013">Table 1</link>) (<link linkend="ch0131s0000li0120">120</link>). During acute infection, these antibodies are bound to HBeAg; the antibody is not detected until the HBeAg levels decrease. Patients who have recovered from acute HBV infection have detectable anti-HBe, anti-HBc, and anti-HBs. Interestingly, patients infected with HBeAg-negative strains of HBV still have anti-HBe (<link linkend="ch0131s0000li0049">49</link>). Patients with chronic HBV who have moved into the inactive carrier stage of infection will also seroconvert and have undetectable HBeAg with detectable anti-HBe.</para>
        <para id="ch0131s0000p0116">Test algorithms for HBeAg and anti-HBe kits vary. Generally, immunoassays have indeterminate or gray zones. If a sample repeatedly yields indeterminate values, additional testing should be performed with a new specimen.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0131s0011">
      <title>Antiviral Susceptibility Testing</title>
      <anchor id="ch0131s0011a0001"/>
      <anchor id="ch0131s0000a0083"/>
      <para id="ch0131s0000p0117">Therapy for HBV usually requires long-term treatment with nucleoside or nucleotide analogs. A disadvantage of long-term therapy is the subsequent development of antiviral resistance. As noted above, HBV replicates through an RNA intermediate. The HBV RNA-dependent DNA polymerase is not precise during rapid replication cycles and does not correctly proofread the final copies, leading to frequent errors. Some of these errors create resistant mutants, which are selected in the presence of antiviral agents (<link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0121">121</link>). Over time, the HBV strains with antiviral resistance become the major viral species. The current recommendation is that a patient who has a 1-log<subscript>10</subscript> increase from the lowest HBV DNA level should be evaluated for the development of antiviral resistance (<link linkend="ch0131s0000li0033">33</link>, <link linkend="ch0131s0000li0049">49</link>, <link linkend="ch0131s0000li0121">121</link>).</para>
      <para id="ch0131s0000p0118">Recently, the nomenclature of HBV antiviral resistance was standardized to track nucleotide changes associated with drug resistance and to recognize new mutations (<link linkend="ch0131s0000li0121">121</link>, <link linkend="ch0131s0000li0122">122</link>). Antiviral resistance mutations can be detected by molecular methods that recognize known mutations associated with resistance (<link linkend="ch0131s0000li0025">25</link>). Methods used to detect these mutations are available; however, the interpretation of results is not always straightforward. Some mutations predict resistance to multiple drugs. A single mutation at A181T is associated with reduced susceptibility to lamivudine, tenofovir, and telbivudine and resistance to adefovir (<link linkend="ch0131s0000li0025">25</link>, <link linkend="ch0131s0000li0036">36</link>, <link linkend="ch0131s0000li0123">123</link>). In other situations, genetic sequence changes may not confer resistance when present alone but do contribute to resistance when additional mutations are present. Many of these single nucleotide changes have no recognized phenotype and may represent the random genetic changes found in viruses that use a reverse transcriptase during replication (<link linkend="ch0131s0000li0036">36</link>, <link linkend="ch0131s0000li0121">121</link>, <link linkend="ch0131s0000li0122">122</link>). For more information on HBV antiviral resistance mutations, see <ulink url="ch0135#ch0135s0001">chapters 115</ulink> and <ulink url="ch0136#ch0136s0001">116</ulink> of this <emphasis>Manual</emphasis>.</para>
      <para id="ch0131s0000p0119">There are currently no FDA-approved commercial IVD kits for resistance genotyping, but testing for antiviral resistance mutations by genetic sequencing is available at reference laboratories (<link linkend="ch0131s0000li0124">124</link>). The INNO-LIPA HBV Multi-DR (Fujirebio Diagnostics, Malvern, PA) is a line probe assay available for diagnostic use in Europe and for research use only (RUO) in the United States. It employs biotinylated amplicons that hybridize to membrane-bound oligonucleotides that represent a mutation sequence. The second-generation line probe assay allows for simultaneous detection of HBV wild-type motif, lamivudine, telbivudine, emtricitabine, adefovir, and entecavir resistance-associated mutations (<link linkend="ch0131s0000li0125">125</link>–<link linkend="ch0131s0000li0128">128</link>). Some disadvantages of line probe assays are that the reading of the reaction lines on each strip can be difficult (up to 34 lines per strip), faint bands can be problematic to interpret, and at times the test results show no bands in viral preparations with known mutations (<link linkend="ch0131s0000li0126">126</link>–<link linkend="ch0131s0000li0128">128</link>).</para>
      <para id="ch0131s0000p0120">Multiple companies market RUO sequencing assays for HBV resistance testing. These reagents may be compatible with both Sanger and next-generation sequencing. Comparison between the sequence assays and the line probe hybridization assay shows a high concordance (<link linkend="ch0131s0000li0129">129</link>).</para>
      <para id="ch0131s0000p0121">A number of individual laboratory-developed assays have been used to detect antiviral mutations in HBV. Sanger DNA sequencing can be used to detect such mutations directly. The advantage of DNA sequencing is that it is accurate and mutations can be identified in any part of the HBV genome (<link linkend="ch0131s0000li0111">111</link>, <link linkend="ch0131s0000li0126">126</link>). However, a serious disadvantage is that these methods lack sensitivity and detect mutants present in 10 to 30% of the viral population. This level of detection does not always consistently identify resistance mutants, which make up at least 10% of the virus population (<link linkend="ch0131s0000li0126">126</link>). Next-generation sequencing is now being used to detect minor viral populations that could emerge during antiviral treatment (<link linkend="ch0131s0000li0128">128</link>, <link linkend="ch0131s0000li0130">130</link>). These HBV variants are present in the patient in low numbers and can have random genetic changes that lead to antiviral drug resistance. During treatment, the HBV variants can be monitored to determine when the patient needs a change in therapy (<link linkend="ch0131s0000li0130">130</link>–<link linkend="ch0131s0000li0136">136</link>). Pyrosequencing and CRISPR-Cas-based assays have also been shown to be very accurate in research settings (<link linkend="ch0131s0000li0137">137</link>, <link linkend="ch0131s0000li0138">138</link>).</para>
      <anchor id="ch0131s0000a0084"/>
      <beginpage pagenum="2175"/>
      <para id="ch0131s0000p0122">Phenotypic testing is used to detect HBV antiviral resistance in research and development laboratories. These methods detect drug resistance based on the use of molecular or cellular techniques or using animal models and are not available for clinical use. Recently, NTCP-overexpressing hepatoma cell lines have been used to screen for antivirals targeting cell entry (<link linkend="ch0131s0000li0139">139</link>, <link linkend="ch0131s0000li0140">140</link>). These novel cell culture systems should provide useful tools not only to improve our understanding of the HBV life cycles, but also in antiviral susceptibility testing.</para>
    </sect1>
    <sect1 id="ch0131s0012">
      <title>Evaluation, Interpretation, and Reporting of Results</title>
      <anchor id="ch0131s0012a0001"/>
      <anchor id="ch0131s0000a0085"/>
      <para id="ch0131s0000p0123">HBV infection leads to several disease presentations, from acute hepatitis with fulminant hepatic failure to chronic hepatitis leading to cirrhosis and/or HCC. The initial assessment for suspected viral hepatitis should include laboratory tests that measure serum transaminases, direct and total bilirubin, albumin and total protein, a complete blood count, coagulation tests, and alpha fetoprotein (<link linkend="ch0131s0000li0036">36</link>). The specific laboratory tests to detect and monitor HBV infection are a mix of viral antigen detection, molecular measurements of HBV DNA, and serologic markers (<link linkend="ch0131s0000li0059">59</link>) (<link linkend="ch0131s0000a0013">Table 1</link>). Patients who are negative for HBsAg, anti-HBc, and HBV DNA are not infected with HBV.</para>
      <para id="ch0131s0000p0124">In a typical acute HBV infection, HBsAg can be detected by immunoassay 2 to 4 weeks before the liver enzyme levels become abnormal and before symptoms appear. Using molecular amplification methods, HBV DNA can be detected before HBsAg and long before the onset of symptoms. During acute HBV disease, once symptoms appear and serum transaminases are elevated, IgM anti-HBc and total anti-HBc are also detectable as liver damage is associated with the immune response. At this phase, a period of peak viral replication, HBeAg may also be detectable. Most patients with an active HBV infection that resolves have anti-HBs that is detectable shortly after the disappearance of HBsAg. The levels of IgM anti-HBc eventually decline over several months as the disease either resolves or becomes chronic.<link linkend="ch0131s0000a0087">Fig. 4</link> illustrates a typical serologic pattern that occurs in patients with an acute HBV infection.</para>
      <figure id="ch0131s0000f0004"><title><anchor id="ch0131s0000a0086"/><phrase role="figureLabel"><anchor id="ch0131s0000a0087"/><link linkend="ch0131s0000a0077">FIGURE 4</link></phrase> Typical sequence of serologic markers in patients with acute HBV infection with resolution of symptoms.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f11.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0125">Note that if HBsAg alone is detected in a blood sample without anti-HBc, rather than early HBV infection, the explanation is usually recent vaccination, since HBsAg can be routinely detectable in blood for 18 days after vaccination, and even up to 52 days in dialysis patients (<link linkend="ch0131s0000li0038">38</link>, <link linkend="ch0131s0000li0141">141</link>). Thus, a history of recent vaccination should be sought and interpretive comments should include this possibility.</para>
      <para id="ch0131s0000p0126">Chronic HBV stages can be distinguished using a combination of laboratory tests and clinical signs (<link linkend="ch0131s0000a0013">Table 1</link>; <anchor id="ch0131s0000a0088"/><link linkend="ch0131s0000a0091">Fig. 5</link>). The immune tolerant phase usually occurs when the patient acquires HBV infection at birth or during early childhood. Infection in this case is associated with a high level of viral production and the presence of HBeAg. There is an absence of liver disease despite high levels of HBV replication, as a consequence of immune tolerance; however, the underlying pathology is poorly understood.</para>
      <para id="ch0131s0000p0127">As the host’s immune response matures, the patient often moves to the immune active phase (also referred to as the HBeAg-positive chronic hepatitis phase), during which HBV-specific epitopes are recognized by the host immune system, leading to immune-mediated injury in the liver. Individuals who acquire HBV perinatally often transition from the immune tolerant phase to the HBeAg-positive chronic hepatitis phase between 20 and 30 years of age. The liver biopsy in this stage shows active inflammation accompanied by fibrosis. Patients who remain HBeAg positive have a higher risk of progressing to liver disease due to the induction of a chronically active immune response by high rates of HBV replication. Such patients have high HBV DNA levels and increased levels of serum transaminases. While HBsAg-positive patients can transmit HBV sexually, percutaneously, or perinatally, individuals with detectable HBeAg pose the highest risk of transmitting HBV to others.</para>
      <para id="ch0131s0000p0128">However, if these individuals develop anti-HBe and HBeAg negativity, they move to the inactive carrier phase (<link linkend="ch0131s0000a0013">Table 1</link>). The transition from the immune tolerant phase to the inactive carrier phase is often not recognized, since patients are often asymptomatic. During the inactive carrier phase, patients can alternate between low and undetectable levels of HBV DNA. The seroconversion to anti-HBe is associated with a decrease in liver damage and the normalization of serum transaminase levels. Mild hepatitis may be noted on biopsy. Many patients remain in this phase for years.</para>
      <anchor id="ch0131s0000a0089"/>
      <beginpage pagenum="2176"/>
      <figure id="ch0131s0000f0005"><title><anchor id="ch0131s0000a0090"/><phrase role="figureLabel"><anchor id="ch0131s0000a0091"/><link linkend="ch0131s0000a0088">FIGURE 5</link></phrase> Typical sequence of serologic markers in patients with HBV infection that progresses to chronicity. In patients with chronic HBV infection both HBsAg and IgG anti-HBc remain persistently detectable generally for life HBeAg is variably present in these patients.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f12.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0129">A portion of inactive HBsAg carriers (about one-third) develop chronic hepatitis which recurs in the absence of HBeAg in their sera (HBeAg-negative chronic hepatitis). These patients are infected with an HBV variant that cannot express HBeAg due to mutations in the precore or core promoter regions of the HBV core gene. Patients with chronic hepatitis that are HBeAg negative are more likely to have more advanced liver disease in spite of lower serum HBV DNA levels.</para>
      <para id="ch0131s0000p0130">Patients infected with an HBsAg escape mutant can test negative for HBsAg but are positive when tested for anti-HBc and HBV DNA. In some individuals the presence of anti-HBc alone may be the only evidence of an active, occult HBV infection of remote origin. These patients, especially those on dialysis, should have HBV DNA testing to exclude a low-level carrier state.</para>
      <para id="ch0131s0000p0131">In a new development, quantitative HBsAg has been proposed as a surrogate marker for transcriptional activity of intrahepatic cccDNA, independent of HBV DNA replication, and thus is increasingly recognized as a useful marker to differentiate phases of chronic HBV (<link linkend="ch0131s0000li0017">17</link>, <link linkend="ch0131s0000li0018">18</link>). Consequently, diagnostic assays are becoming available to inform HBV prognosis and therapy.</para>
      <para id="ch0131s0000p0132">Passive transfer of anti-HBs or anti-HBc may be observed in neonates of mothers with current or past HBV infections. However, passive-antibody levels decline gradually over 3 to 6 months, while levels of antibody induced by infection are stable over many years. Since blood donations are tested for HBsAg and total anti-HBc, passive transfer of these HBV markers following blood transfusions is unlikely.</para>
      <para id="ch0131s0000p0133">Anti-HBs without anti-HBc develops in individuals who receive hepatitis B vaccine (which contains only HBsAg), and anti-HBs levels of ≥10 mIU/ml are considered protective. Most individuals vaccinated for HBV have detectable levels of anti-HBs; however, some vaccinated people test negative due to waning levels of anti-HBs. They usually respond to a challenge dose of HBsAg vaccine with an anamnestic response in approximately 2 weeks. Studies of vaccinated individuals who no longer have detectable anti-HBs show that infection can occur but is blunted by the anamnestic anti-HBs response such that liver damage is minimal and symptoms do not occur. In contrast, an HBsAg-negative carrier may fail to produce detectable levels of anti-HBs after vaccination. Individuals who do not have a detectable response to the first series of HBV vaccine should be given a second vaccine series. Individuals who do not respond to the second vaccination series should be considered susceptible to HBV infection and should be given HBV immunoglobulin prophylaxis after any known exposure to HBV-positive body fluid. It is important to note that some HBV vaccine nonresponders are chronically infected with HBV. Thus, individuals who do not have detectable anti-HBs after two vaccine series should be tested for HBsAg and anti-HBc.</para>
      <para id="ch0131s0000p0134">Testing for the HBV genotype is currently not required except for selected patients from regions around the world that have variability in HBV genotypes (<link linkend="ch0131s0000a0075">Table 4</link>). While the “gold standard” for assessing inflammatory activity (grade) and degree of fibrosis (stage) is the liver biopsy, noninvasive assessments of liver fibrosis are increasingly used in lieu of biopsy (<link linkend="ch0131s0000li0143">143</link>).</para>
      <para id="ch0131s0000p0135">Molecular assays are used to determine HBV DNA levels and contribute to establishing the stage of disease in newly diagnosed patients. They are also used to monitor patients on antiviral therapy. The reduction of HBV DNA during antiviral therapy is a measure of treatment response and predicts histologic improvement. Increasing HBV DNA levels are associated with chronic liver disease, cirrhosis, and possibly death. The WHO standard for HBV DNA has helped standardization of HBV DNA assays, and results are now reported in international units per milliliter.</para>
      <para id="ch0131s0000p0136">Antiviral therapy is given to patients to prevent progression of liver disease. The decision to begin therapy is generally based on the presence or absence of cirrhosis, the alanine aminotransferase level, HBeAg status, and the HBV DNA level (<link linkend="ch0131s0000li0143">143</link>). During the course of therapy, treatment response is monitored using biochemical, virologic, serologic, and histologic results. Currently, the most accurate monitor of virologic activity is the HBV DNA level, using an assay with a wide dynamic range. The loss of HBsAg, seroconversion to anti-HBs, and long-lasting suppression of HBV DNA indicate a successful response to therapy. Patients who appear to have suppressed HBV DNA levels are monitored periodically because relapse due to antiviral resistance is possible. The most reliable measure of a successful long-term treatment response is the sustained suppression of HBV DNA, while HBsAg seroconversion is the ultimate goal.</para>
      <para id="ch0131s0000p0137">In addition, treatment of pregnant women with HBV viral loads of &gt;200,000 IU/ml is recommended beginning in the third trimester, regardless of alanine aminotransferase levels, to reduce the risk of perinatal transmission (<link linkend="ch0131s0000li0142">142</link>). All patients with HCC should be treated, and patients with chronic HBV starting immunosuppressive drugs should be given prophylactic therapy to prevent HBV reactivation (<link linkend="ch0131s0000li0142">142</link>, <link linkend="ch0131s0000li0143">143</link>). Treatment of hepatitis C virus with direct-acting antivirals can lead to HBV reactivation in coinfected patients (<link linkend="ch0131s0000li0144">144</link>), and thus patients should be either treated for HBV or monitored for reactivation at regular intervals if treatment criteria are not met (<link linkend="ch0131s0000li0142">142</link>, <link linkend="ch0131s0000li0143">143</link>).</para>
      <para id="ch0131s0000p0138">When HBV DNA levels increase by 1 log<subscript>10</subscript> in a patient taking antiviral treatment, it may indicate antiviral resistance. It is not recommended that resistance testing be performed before starting therapy, even if the patient has a very high viral level. Resistance detection is useful only after a patient has been treated for several months and fails to show an HBV DNA reduction of at least 1 log<subscript>10.</subscript> Such patients are classified as primary nonresponders. They should be tested for the presence of resistant mutants to assist in selecting a new treatment regimen. For successfully treated patients who have a virologic breakthrough, antiviral resistance testing should also be performed to determine selection of resistant viral strains.</para>
      <para id="ch0131s0000p0139">In summary, diagnostic testing is essential for HBV prevention and treatment. Thus, increasing the accessibility and uptake of diagnostic testing in all resource settings is essential in reducing the disease burden worldwide. Strategies include using dried blood spots for testing and implementing rapid antigen and molecular testing, including at the point of care (63–65, 92, 143). Most important, however, is linking patients to appropriate followup health care.</para>
      <sect2 id="ch0131s0012s0001">
        <title>HEPATITIS D VIRUS</title>
        <anchor id="ch0131s0012a0002"/>
        <anchor id="ch0131s0000a0092"/>
        <anchor id="ch0131s0000a0093"/>
      </sect2>
    </sect1>
    <sect1 id="ch0131s0013">
      <title>Taxonomy and Description of the Agent</title>
      <anchor id="ch0131s0013a0001"/>
      <anchor id="ch0131s0000a0094"/>
      <para id="ch0131s0000p0140">Hepatitis D virus (HDV) is the only virus in the genus<emphasis>Deltaviridae.</emphasis> It is a small RNA virus that encodes a single protein and which requires the HBV-encoded HBsAg for its assembly and transmission. Thus, it is a subviral particle rather than a true virus (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0146">146</link>). HDV was first described in 1977 in Italian patients with chronic HBV who developed episodes of serious acute disease (<link linkend="ch0131s0000li0147">147</link>). HDV is generally spherical, with an average diameter ranging from 36 to 43 nm. The circular, single-stranded, negative-sense 1.7-kb RNA genome of HDV encodes only a single protein, the HDV nucleocapsid protein, known as the hepatitis delta antigen (HDAg). It is non-glycosylated and is produced in two isoforms: a small form (S-HDAg) consisting of a 195-amino-acid 24-kDa protein and a large form (L-HDAg) consisting of a 214-amino-acid 27-kDa protein (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0146">146</link>). The protein cannot assemble into viral particles without the presence of HBsAg. The HDV RNA genome is surrounded by HDAg, which is surrounded by HBsAg. Consequently, HDAg is undetectable on the complete HDV particle. In spite of this, infected individuals produce antibody to the HDV antigen (anti-HDV). However, anti-HDV does not neutralize this particle, whereas anti-HBs does have neutralizing activity (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0146">146</link>).</para>
      <para id="ch0131s0000p0141">HDV relies on host cell machinery for replication, and the viral genome (and antigenome) serves as a ribozyme for self-ligation and cleavage (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0146">146</link>). Similar to HBV, HDV binds to hepatocytes via the hepatocyte-specific receptor NTCP (<link linkend="ch0131s0000li0146">146</link>, <link linkend="ch0131s0000li0148">148</link>) (<link linkend="ch0131s0000a0029">Fig. 2</link>). The replication of the HDV genome uses the host RNA polymerase II rather than an HDV- or HBV-encoded RNA polymerase. The only enzymatic activity inherent to HDV is mediated by RNA elements termed ribozymes which cleave the newly synthesized, circular RNA genomes, producing linear molecules (<link linkend="ch0131s0000li0146">146</link>). After that cleavage, replication of the HDV genome occurs via a rolling-circle mechanism with self-cleavage (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0146">146</link>). The assembly of HDV virion requires the farnesylation by the host of the L-HDAg (<link linkend="ch0131s0000li0149">149</link>).</para>
    </sect1>
    <sect1 id="ch0131s0014">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0131s0014a0001"/>
      <anchor id="ch0131s0000a0095"/>
      <para id="ch0131s0000p0142">Worldwide, it is estimated that approximately 15 to 20 million people are HDV carriers (<link linkend="ch0131s0000li0150">150</link>, <link linkend="ch0131s0000li0151">151</link>). Several areas of the world have a high prevalence of HDV-infected individuals, including countries bordering the Mediterranean, the Middle East, Central Asia, West Africa, the Amazon Basin, and the South Pacific Islands (<link linkend="ch0131s0000li0150">150</link>, <link linkend="ch0131s0000li0151">151</link>). In these areas of endemicity, HDV appears to be transmitted by close person-to-person spread, such as household contact. Additionally, many individuals have acquired HDV through exposure to blood-contaminated needles and blood products. Persistent epidemics of severe acute HDV have been observed in these populations, which have high HBV carrier rates (<link linkend="ch0131s0000li0150">150</link>, <link linkend="ch0131s0000li0151">151</link>). Eight genotypes of HDV have been identified, each with its own distinct geographic distributions and outcomes. While HDV isolates of genotype 1 are the most common and have been reported in every part of the world (<link linkend="ch0131s0000li0152">152</link>, <link linkend="ch0131s0000li0153">153</link>), the other seven genotypes are more localized, with genotypes 2 and 4 mainly confined to Asia, genotype 3 to Latin America, and genotypes 5 through 8 to Africa (<link linkend="ch0131s0000li0152">152</link>).</para>
    </sect1>
    <sect1 id="ch0131s0015">
      <title>Clinical Significance</title>
      <anchor id="ch0131s0015a0001"/>
      <anchor id="ch0131s0000a0096"/>
      <para id="ch0131s0000p0143">HDV can be transmitted only to individuals who are infected with HBV already or when both viral agents are transmitted together. A coinfection occurs when a naive individual is infected simultaneously with both viruses; coinfection occurs in only 2% of cases (<anchor id="ch0131s0000a0097"/><link linkend="ch0131s0000a0101">Fig. 6</link>) (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0151">151</link>). A superinfection occurs when an individual chronically infected with HBV is infected with HDV (<anchor id="ch0131s0000a0098"/><link linkend="ch0131s0000a0103">Fig. 7</link>) (<link linkend="ch0131s0000li0145">145</link>). Superinfection occurs in more than 90% of infected patients (<link linkend="ch0131s0000li0151">151</link>). Acute HDV superinfection has a greater risk of fulminant hepatitis and liver failure than HBV infection alone. Likewise, chronic HDV infection is the most severe form of viral hepatitis, which is associated with more rapidly progressing liver damage than infection with HBV alone (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0151">151</link>).</para>
      <para id="ch0131s0000p0144">Rates of fulminant hepatitis can be as high as 5% in patients with HBV and HDV coinfection (<link linkend="ch0131s0000li0145">145</link>, <link linkend="ch0131s0000li0151">151</link>). A biphasic clinical course is sometimes observed during coinfection. HDV infection does not increase the rate of chronicity of acute HBV but may convert an asymptomatic or mild, chronic HBV infection into a rapidly progressive, fulminant or severe disease (<link linkend="ch0131s0000li0151">151</link>, <link linkend="ch0131s0000li0154">154</link>). The failure of HBV-specific nucleoside analogues to suppress the HBV helper function, and the limitations of experimental systems to study the HDV life cycle, have impeded the development of HDV-specific drugs (<link linkend="ch0131s0000li0155">155</link>).</para>
      <anchor id="ch0131s0000a0099"/>
      <beginpage pagenum="2178"/>
      <figure id="ch0131s0000f0006"><title><anchor id="ch0131s0000a0100"/><phrase role="figureLabel"><anchor id="ch0131s0000a0101"/><link linkend="ch0131s0000a0097">FIGURE 6</link></phrase> Serologic course of HDV infection with resolution when the virus is acquired as a co-infection with HBV.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f13.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0131s0000f0007"><title><anchor id="ch0131s0000a0102"/><phrase role="figureLabel"><anchor id="ch0131s0000a0103"/><link linkend="ch0131s0000a0098">FIGURE 7</link></phrase> Serologic course of HDV infection when the virus is acquired as a superinfection with HBV. Symptoms and alanine aminotransferase ALT levels are shown to indicate the intermittent nature of symptoms and liver involvement.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0131f07.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0131s0000p0145">The newest knowledge on the interaction of HDV with the NTCP receptor (<link linkend="ch0131s0000li0148">148</link>) and the farnesylation process of L-HDAg (<link linkend="ch0131s0000li0149">149</link>) has led to new therapeutic proposals. Three therapeutic strategies are in evaluation (<link linkend="ch0131s0000li0155">155</link>): (i) Myrcludex B, a myristolated lipopeptide of the pre-S1 domain of the HBsAg that blocks the entry of the HDV into hepatocytes and controls infection by preventing the spreading of the virus to liver cells not infected by the HBV (<link linkend="ch0131s0000li0156">156</link>, <link linkend="ch0131s0000li0157">157</link>); (ii) Lonafarnib, an inhibitor of a host farnesyl-transferase that hinders morphogenesis of the HDV by preventing the farnesylation of the large HD antigen, necessary for virion assembly (<link linkend="ch0131s0000li0158">158</link>, <link linkend="ch0131s0000li0159">159</link>); and (iii) REP 2139, a nucleic acid polymer that prevents export of the mature HDV by the presumed inhibition of the synthesis of subviral HBsAg particles with which the virion is coated (<link linkend="ch0131s0000li0160">160</link>, <link linkend="ch0131s0000li0161">161</link>). Myrcludex B, Lonafarnib, and REP 2139 so far represent expected and promising therapeutic options for HDV infection. Further studies are needed to define the utility of combination therapy with pegylated interferon alpha 2a (<link linkend="ch0131s0000li0155">155</link>, <link linkend="ch0131s0000li0162">162</link>). Successful vaccination for HBV also prevents HDV infection, since HDV cannot replicate in the absence of a concurrent HBV infection.</para>
    </sect1>
    <sect1 id="ch0131s0016">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0131s0016a0001"/>
      <anchor id="ch0131s0000a0104"/>
      <para id="ch0131s0000p0146">HDV infection is diagnosed by serologic and molecular markers using serum or plasma and is suspected for HBV-infected patients from countries in which HDV is prevalent (<link linkend="ch0131s0000li0163">163</link>, <link linkend="ch0131s0000li0164">164</link>). Patients with chronic hepatitis B not responding to antiviral treatment, or with liver damage despite a low viral load (HBV DNA &lt;2,000 IU/ml), should also be tested.</para>
    </sect1>
    <sect1 id="ch0131s0017">
      <title>Direct Detection</title>
      <anchor id="ch0131s0017a0001"/>
      <anchor id="ch0131s0000a0105"/>
      <para id="ch0131s0000p0147">HDV infections can be diagnosed by detecting HDAg or, more recently, HDV RNA in serum and in liver tissue. Currently, the most common method for HDV RNA detection is reverse transcription real-time PCR (<link linkend="ch0131s0000li0164">164</link>–<link linkend="ch0131s0000li0167">167</link>). While liver ultrasounds, elastrography, and fibroscans remain the effective ways of monitoring chronic HDV progression, a declining HDV RNA level usually indicates a response to treatment (<link linkend="ch0131s0000li0168">168</link>, <link linkend="ch0131s0000li0169">169</link>). Qualitative and quantitative HDV RNA tests are now available in major reference laboratories. A recent study reported the use of droplet digital PCR for absolute quantification of HDV-RNA, providing the clinical and diagnostic management of delta hepatitis (<link linkend="ch0131s0000li0170">170</link>).</para>
    </sect1>
    <sect1 id="ch0131s0018">
      <title>Typing</title>
      <anchor id="ch0131s0018a0001"/>
      <anchor id="ch0131s0000a0106"/>
      <para id="ch0131s0000p0148">Sequencing has been the sole technique used for HDV genotype determination. Although it is unclear if differences in the HDV genome play a role in disease presentation, this genomic diversity is likely related to discrepant results in HDV IgM antibodies and HDV viral loads between clinical laboratories, as reported in a recent French national quality control study (<link linkend="ch0131s0000li0153">153</link>, <link linkend="ch0131s0000li0163">163</link>).</para>
    </sect1>
    <sect1 id="ch0131s0019">
      <title>Serologic Tests</title>
      <anchor id="ch0131s0019a0001"/>
      <anchor id="ch0131s0000a0107"/>
      <para id="ch0131s0000p0149">Several commercial devices are available for total antibodies to HDV, including the ETI-AB-DELTAK-2 assay DiaPro HDV Ab (Diagnostic Bioprobes, Milan, Italy), DiaSorin ETI-AB-DELTAK-2 (Sorin, Saluggia, Italy), and GB HDV Ab (General Biologicals Corp, Hsinchu, Taiwan) (<link linkend="ch0131s0000li0163">163</link>, <link linkend="ch0131s0000li0164">164</link>, <link linkend="ch0131s0000li0171">171</link>, <link linkend="ch0131s0000li0172">172</link>). In an ELISA format, these assays measure all types of antibodies to HDV; however, antibodies other than IgG are a minority, and in practice the measure of total antibodies is synonymous with the measure of IgG antibodies. The IgG antibody is not protective and may persist for years in superinfected patients who clear HDV infection and remain HBsAg positive (<link linkend="ch0131s0000li0173">173</link>). The IgM antibody to HDAg (anti-HDV IgM) is measured with μ-capture immunoassays (<link linkend="ch0131s0000li0174">174</link>). Three commercial assays are available, the DiaPro HDV IgM (Diagnostic Bioprobes, Milan, Italy), the ETI-D elta-I gM-K 2 assay (Sorin, Saluggia, Italy) and the AntiHD IgM Kit (Abbott, Serono, Italy). Anti-HDV IgM testing can help to determine disease activity and to predict treatment response (<link linkend="ch0131s0000li0175">175</link>, <link linkend="ch0131s0000li0176">176</link>).</para>
    </sect1>
    <sect1 id="ch0131s0020">
      <title>Evaluation, Interpretation, and Reporting of Results</title>
      <anchor id="ch0131s0020a0001"/>
      <anchor id="ch0131s0000a0108"/>
      <para id="ch0131s0000p0150">Recently, there has been a resurgence of interest in HDV infections, due to improvements in diagnostic testing and emerging new therapies. HDV infections lead to more serious liver diseases than HBV infection alone, such as faster progression to liver fibrosis, increased risk of liver cancer, and earlier decompensated cirrhosis and liver failure. It is important that people with HBV/HDV coinfection be diagnosed early. The first step in the diagnosis of HDV infection is testing HBsAg-positive individuals for anti-HDV antibody using commercially available kits. In anti-HDV-positive patients, HDV RNA in serum is tested to determine whether the antibody reflects an ongoing active HDV infection or represents a past HDV infection. In the HDV-positive individual with liver disease, it is critical to distinguish acute HDV/HBV coinfection from chronic HDV superinfection in HBsAg carriers; the course, prognosis, and management of the two conditions are different.</para>
      <para id="ch0131s0000p0151">The differential diagnosis can be achieved through testing a battery of HDV and HBV markers, which combine in patterns characteristic for each condition. Standardized commercial assays are available to determine IgG and IgM antibodies to HDV. Several laboratory-developed tests to qualitatively and quantitatively detect HDV RNA in plasma or serum are available in major reference laboratories. These molecular results should be interpreted with caution because they are not yet standardized and the sensitivities and the results from different laboratories can vary (<link linkend="ch0131s0000li0168">168</link>).</para>
      <sect2 id="ch0131s0020s0001">
        <title>REFERENCES</title>
        <anchor id="ch0131s0020a0002"/>
        <anchor id="ch0131s0000a0109"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0131s0000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Blumberg BS, Alter HJ, Visnich S.</emphasis> 1965. A “new” antigen in leukemia sera. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">191:</emphasis>541–546.</para>
          </listitem>
          <listitem id="ch0131s0000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Seeger CFZ, Mason WS.</emphasis> 2013. Hepadnaviruses, p 2185–2221. <citetitle><emphasis>In</emphasis></citetitle> Fields BN, Knipe DM, Howley PM (ed), <citetitle><emphasis>Fields Virology</emphasis></citetitle>, 6th ed. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins, Philadelphia, PA.</para>
          </listitem>
          <listitem id="ch0131s0000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Dane DS, Cameron CH, Briggs M.</emphasis> 1970. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">1:</emphasis>695–698.</para>
          </listitem>
          <listitem id="ch0131s0000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF.</emphasis> 2016. Cell culture models for the investigation of hepatitis B and D virus infection. <citetitle><emphasis>Viruses</emphasis></citetitle> <emphasis role="strong">8:</emphasis>261.</para>
          </listitem>
          <listitem id="ch0131s0000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Ni Y, Urban S.</emphasis> 2017. Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">1540:</emphasis>15–25.</para>
          </listitem>
          <listitem id="ch0131s0000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP.</emphasis> 2019. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">71:</emphasis>289–300.</para>
          </listitem>
          <listitem id="ch0131s0000li0007" role="bibliographyEntry">
            <anchor id="ch0131s0000a0110"/>
            <para>7.<emphasis role="strong">Yang F, Yu X, Zhou C, Mao R, Zhu M, Zhu H, Ma Z, Mitra B, Zhao G, Huang Y, Guo H, Wang B, Zhang J.</emphasis> 2019. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e1007690.</para>
          </listitem>
          <listitem id="ch0131s0000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S.</emphasis> 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">146:</emphasis>1070–1083.</para>
          </listitem>
          <listitem id="ch0131s0000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W.</emphasis> 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. <citetitle><emphasis>eLife</emphasis></citetitle> <emphasis role="strong">1:</emphasis>e00049.</para>
          </listitem>
          <listitem id="ch0131s0000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Li W.</emphasis> 2015. The hepatitis B virus receptor. <citetitle><emphasis>Annu Rev Cell Dev Biol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>125–147.</para>
          </listitem>
          <listitem id="ch0131s0000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Hu Q, Zhang F, Duan L, Wang B, Ye Y, Li P, Li D, Yang S, Zhou L, Chen W.</emphasis> 2020. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution. <citetitle><emphasis>Front Cell Infect Microbiol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>74.</para>
          </listitem>
          <listitem id="ch0131s0000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K.</emphasis> 2019. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">116:</emphasis>8487–8492.</para>
          </listitem>
          <listitem id="ch0131s0000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Herrscher C, Roingeard P, Blanchard E.</emphasis> 2020. Hepatitis B virus entry into cells. <citetitle><emphasis>Cells</emphasis></citetitle> <emphasis role="strong">9:</emphasis>1486</para>
          </listitem>
          <listitem id="ch0131s0000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Herrscher C, Pastor F, Burlaud-Gaillard J, Dumans A, Seigneuret F, Moreau A, Patient R, Eymieux S, de Rocquigny H, Hourioux C, Roingeard P, Blanchard E.</emphasis> 2020. Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis. <citetitle><emphasis>Cell Microbiol</emphasis></citetitle> <emphasis role="strong">22:</emphasis>e13205.</para>
          </listitem>
          <listitem id="ch0131s0000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Huang HC, Chen CC, Chang WC, Tao MH, Huang C.</emphasis> 2012. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">86:</emphasis>9443–9453.</para>
          </listitem>
          <listitem id="ch0131s0000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Oropeza CE, Tarnow G, Sridhar A, Taha TY, Shalaby RE, McLachlan A.</emphasis> 2020. The regulation of HBV transcription and replication. <citetitle><emphasis>Adv Exp Med Biol</emphasis></citetitle> <emphasis role="strong">1179:</emphasis>39–69.</para>
          </listitem>
          <listitem id="ch0131s0000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL.</emphasis> 2017. The role of quantitative hepatitis B surface antigen revisited. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>398–411.</para>
          </listitem>
          <listitem id="ch0131s0000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Thibault V, Servant-Delmas A, Ly TD, Roque-Afonso AM, Laperche S.</emphasis> 2017. Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">89:</emphasis>14–21.</para>
          </listitem>
          <listitem id="ch0131s0000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Trépo C, Chan HL, Lok A.</emphasis> 2014. Hepatitis B virus infection. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">384:</emphasis>2053–2063.</para>
          </listitem>
          <listitem id="ch0131s0000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Tong S, Revill P.</emphasis> 2016. Overview of hepatitis B viral replication and genetic variability. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">64</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S4–S16.</para>
          </listitem>
          <listitem id="ch0131s0000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Mak LY, Seto WK, Fung J, Yuen MF.</emphasis> 2020. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <citetitle><emphasis>Hepatol Int</emphasis></citetitle> <emphasis role="strong">14:</emphasis>35–46.</para>
          </listitem>
          <listitem id="ch0131s0000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T,</emphasis> van <emphasis role="strong">Bömmel F.</emphasis> 2021. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">74:</emphasis>283–292.</para>
          </listitem>
          <listitem id="ch0131s0000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Liaw YF.</emphasis> 2019. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. <citetitle><emphasis>Nat Rev Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>631–641.</para>
          </listitem>
          <listitem id="ch0131s0000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Venkatakrishnan B, Zlotnick A.</emphasis> 2016. The structural biology of hepatitis B virus: form and function. <citetitle><emphasis>Annu Rev Virol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>429–451.</para>
          </listitem>
          <listitem id="ch0131s0000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Lapi</emphasis>ń<emphasis role="strong">ski TW, Pogorzelska J, Flisiak R.</emphasis> 2012. HBV mutations and their clinical significance. <citetitle><emphasis>Adv Med Sci</emphasis></citetitle> <emphasis role="strong">57:</emphasis>18–22.</para>
          </listitem>
          <listitem id="ch0131s0000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Kajiwara E, Tanaka Y, Ohashi T, Uchimura K, Sadoshima S, Kinjo M, Mizokami M.</emphasis> 2008. Hepatitis B caused by a hepatitis B surface antigen escape mutant. <citetitle><emphasis>J Gastroenterol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>243–247.</para>
          </listitem>
          <listitem id="ch0131s0000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Rajoriya N, Combet C, Zoulim F, Janssen HLA.</emphasis> 2017. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1281–1297.</para>
          </listitem>
          <listitem id="ch0131s0000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">World Health Organization.</emphasis> 2021. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. World Health Organization, Genenva, Switzerland.</para>
          </listitem>
          <listitem id="ch0131s0000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">World Health Organization.</emphasis> 2017. Global hepatitis report, 2017. World Health Organization, Geneva, Switzerland. <ulink url="https://www.who.int/publications/i/item/9789241565455">https://www.who.int/publications/i/item/9789241565455</ulink>.</para>
          </listitem>
          <listitem id="ch0131s0000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ.</emphasis> 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">386:</emphasis>1546–1555.</para>
          </listitem>
          <listitem id="ch0131s0000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Chang MS, Nguyen MH.</emphasis> 2017. Epidemiology of hepatitis B and the role of vaccination. <citetitle><emphasis>Best Pract Res Clin Gastroenterol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>239–247.</para>
          </listitem>
          <listitem id="ch0131s0000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Nelson NP, Easterbrook PJ, McMahon BJ.</emphasis> 2016. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. <citetitle><emphasis>Clin Liver Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>607–628.</para>
          </listitem>
          <listitem id="ch0131s0000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB.</emphasis> 2018. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1560–1599.</para>
          </listitem>
          <listitem id="ch0131s0000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT.</emphasis> 2009. National Institutes of Health consensus development conference statement: management of hepatitis B. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S4–S12.</para>
          </listitem>
          <listitem id="ch0131s0000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Wilkins T, Sams R, Carpenter M.</emphasis> 2019. Hepatitis B: screening, prevention, diagnosis, and treatment. <citetitle><emphasis>Am Fam Physician</emphasis></citetitle> <emphasis role="strong">99:</emphasis>314–323.</para>
          </listitem>
          <listitem id="ch0131s0000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F, European Association for the Study of the Liver. Electronic address: <ulink url="mailto:easloffice@easloffice.eu">easloffice@easloffice.eu</ulink>, European Association for the Study of the Liver.</emphasis> 2017. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>370–398.</para>
          </listitem>
          <listitem id="ch0131s0000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K.</emphasis> 2016. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">63:</emphasis>284–306.</para>
          </listitem>
          <listitem id="ch0131s0000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP.</emphasis> 2018. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1–31.</para>
          </listitem>
          <listitem id="ch0131s0000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Likhitsup A, Lok AS.</emphasis> 2019. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. <citetitle><emphasis>Clin Liver Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>401–416.</para>
          </listitem>
          <listitem id="ch0131s0000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Lozano R, et al.</emphasis> 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">380:</emphasis>2095–2128.</para>
          </listitem>
          <listitem id="ch0131s0000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Dandri M, Petersen J.</emphasis> 2016. Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">62</emphasis>(Suppl 4)<emphasis role="strong">:</emphasis>S281–S288.</para>
          </listitem>
          <listitem id="ch0131s0000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M.</emphasis> 2019. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. <citetitle><emphasis>Int J Mol Sci</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1358.</para>
          </listitem>
          <listitem id="ch0131s0000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh MP.</emphasis> 2019. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. <citetitle><emphasis>Microb Pathog</emphasis></citetitle> <emphasis role="strong">128:</emphasis>184–194.</para>
          </listitem>
          <listitem id="ch0131s0000li0044" role="bibliographyEntry">
            <anchor id="ch0131s0000a0111"/>
            <para>44.<emphasis role="strong">Chen BF.</emphasis> 2018. Hepatitis B virus pre-S/S variants in liver diseases. <citetitle><emphasis>World J Gastroenterol</emphasis></citetitle> <emphasis role="strong">24:</emphasis>1507–1520.</para>
          </listitem>
          <listitem id="ch0131s0000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Geng M, Xin X, Bi LQ, Zhou LT, Liu XH.</emphasis> 2015. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. <citetitle><emphasis>World J Gastroenterol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>10732–10738.</para>
          </listitem>
          <listitem id="ch0131s0000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Sartorius K, Makarova J, Sartorius B, An P, Winkler C, Chuturgoon A, Kramvis A.</emphasis> 2019. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis. <citetitle><emphasis>Cells</emphasis></citetitle> <emphasis role="strong">8:</emphasis>1504.</para>
          </listitem>
          <listitem id="ch0131s0000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB.</emphasis> 2018. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. <citetitle><emphasis>Abdom Radiol (NY)</emphasis></citetitle> <emphasis role="strong">43:</emphasis>13–25.</para>
          </listitem>
          <listitem id="ch0131s0000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS, Group HBVS, HBV-23 Study Group.</emphasis> 2018. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">36:</emphasis>668–674.</para>
          </listitem>
          <listitem id="ch0131s0000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T.</emphasis> 2015. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">121:</emphasis>47–58.</para>
          </listitem>
          <listitem id="ch0131s0000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Tang LSY, Covert E, Wilson E, Kottilil S.</emphasis> 2018. Chronic hepatitis B infection: a review. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">319:</emphasis>1802–1813.</para>
          </listitem>
          <listitem id="ch0131s0000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG.</emphasis> 2017. Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1283–1288.</para>
          </listitem>
          <listitem id="ch0131s0000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.</emphasis> 2015. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1314–1326.</para>
          </listitem>
          <listitem id="ch0131s0000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL, Wilt TJ.</emphasis> 2009. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">150:</emphasis>111–124.</para>
          </listitem>
          <listitem id="ch0131s0000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P, GS-US-320-0108 Investigators.</emphasis> 2016. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <citetitle><emphasis>Lancet Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">1:</emphasis>196–206.</para>
          </listitem>
          <listitem id="ch0131s0000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K, GS-US-320-0110 Investigators.</emphasis> 2016. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <citetitle><emphasis>Lancet Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">1:</emphasis>185–195.</para>
          </listitem>
          <listitem id="ch0131s0000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Urban S, Bartenschlager R, Kubitz R, Zoulim F.</emphasis> 2014. Strategies to inhibit entry of HBV and HDV into hepatocytes. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">147:</emphasis>48–64.</para>
          </listitem>
          <listitem id="ch0131s0000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Kang C, Syed YY.</emphasis> 2020. Bulevirtide: first Approval. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">80:</emphasis>1601–1605.</para>
          </listitem>
          <listitem id="ch0131s0000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Lopatin U.</emphasis> 2019. Drugs in the Pipeline for HBV. <citetitle><emphasis>Clin Liver Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>535–555.</para>
          </listitem>
          <listitem id="ch0131s0000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G.</emphasis> 2020. Hepatitis B virus: advances in prevention, diagnosis, and therapy. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">33:</emphasis>33.</para>
          </listitem>
          <listitem id="ch0131s0000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P.</emphasis> 2019. HBV immune-therapy: from molecular mechanisms to clinical applications. <citetitle><emphasis>Int J Mol Sci</emphasis></citetitle> <emphasis role="strong">20:</emphasis>2754.</para>
          </listitem>
          <listitem id="ch0131s0000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Baleriola C, Johal H, Jacka B, Chaverot S, Bowden S, Lacey S, Rawlinson W.</emphasis> 2011. Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at −20°C and −70°C. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3163–3167.</para>
          </listitem>
          <listitem id="ch0131s0000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, WHO Collaborative Study Group.</emphasis> 2001. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. <citetitle><emphasis>Vox Sang</emphasis></citetitle> <emphasis role="strong">80:</emphasis>63–71.</para>
          </listitem>
          <listitem id="ch0131s0000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Valdes A, Martinez M, Esteban R, Guardia J.</emphasis> 2004. Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">40:</emphasis>133–139.</para>
          </listitem>
          <listitem id="ch0131s0000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Villar LM, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL.</emphasis> 2011. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">83:</emphasis>1522–1529.</para>
          </listitem>
          <listitem id="ch0131s0000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Zanoni M, Giron LB, Vilhena C, Sucupira MC, Lloyd RM Jr, Diaz RS.</emphasis> 2012. Comparative effectiveness of dried-plasma hepatitis B virus viral load (VL) testing in three different VL commercial platforms using ViveST for sample collection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>145–147.</para>
          </listitem>
          <listitem id="ch0131s0000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Villar LM, Bezerra CS, Cruz HM, Portilho MM, Flores GL.</emphasis> 2019. Applicability of oral fluid and dried blood spot for hepatitis B virus diagnosis. <citetitle><emphasis>Can J Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">2019:</emphasis>5672795.</para>
          </listitem>
          <listitem id="ch0131s0000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Cruz HM, de Paula VS, da Silva EF, do Ó KMR, Milagres FAP, Cruz MS, Bastos FI, da Mota JC, Pollo-Flores P, Leal E, Motta-Castro ARC, Lewis-Ximenez LL, Lampe E, Villar LM.</emphasis> 2019. Utility of oral fluid samples for hepatitis B antibody detection in real life conditions. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>632.</para>
          </listitem>
          <listitem id="ch0131s0000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Than TT, Jo E, Todt D, Nguyen PH, Steinmann J, Steinmann E, Windisch MP.</emphasis> 2019. High environmental stability of hepatitis B virus and inactivation requirements for chemical biocides. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">219:</emphasis>1044–1048.</para>
          </listitem>
          <listitem id="ch0131s0000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Bhat M, Ghali P, Deschenes M, Wong P.</emphasis> 2012. Hepatitis B and the infected health care worker: public safety at what cost? <citetitle><emphasis>Can J Gastroenterol</emphasis></citetitle> <emphasis role="strong">26:</emphasis>257–260.</para>
          </listitem>
          <listitem id="ch0131s0000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Coffin CS, Zhou K, Terrault NA.</emphasis> 2019. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">156:</emphasis>355–368.e3.</para>
          </listitem>
          <listitem id="ch0131s0000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L.</emphasis> 2019. A global view to HBV chronic infection: evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals. <citetitle><emphasis>Int J Environ Res Public Health</emphasis></citetitle> <emphasis role="strong">16:</emphasis>3307.</para>
          </listitem>
          <listitem id="ch0131s0000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, Glebe D.</emphasis> 2010. Occult hepatitis B virus infection: detection and significance. <citetitle><emphasis>Dig Dis</emphasis></citetitle> <emphasis role="strong">28:</emphasis>116–125.</para>
          </listitem>
          <listitem id="ch0131s0000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Amini A, Varsaneux O, Kelly H, Tang W, Chen W, Boeras DI, Falconer J, Tucker JD, Chou R, Ishizaki A, Easterbrook P, Peeling RW.</emphasis> 2017. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>698.</para>
          </listitem>
          <listitem id="ch0131s0000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF.</emphasis> 2018. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <citetitle><emphasis>Aliment Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">47:</emphasis>43–54.</para>
          </listitem>
          <listitem id="ch0131s0000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Inoue T, Tanaka Y.</emphasis> 2019. The role of hepatitis B core-related antigen. <citetitle><emphasis>Genes (Basel)</emphasis></citetitle> <emphasis role="strong">10:</emphasis>357.</para>
          </listitem>
          <listitem id="ch0131s0000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F.</emphasis> 2019. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>615–625.</para>
          </listitem>
          <listitem id="ch0131s0000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Gencay M, Seffner A, Pabinger S, Gautier J, Gohl P, Weizenegger M, Neofytos D, Batrla R, Woeste A, Kim HS, Westergaard G, Reinsch C, Brill E, Thuy PTT, Hoang BH, Sonderup M, Spearman CW, Brancaccio G, Fasano M, Gaeta GB, Santantonio T, Kaminski WE.</emphasis> 2018. Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays. <citetitle><emphasis>J Viral Hepat</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1132–1138.</para>
          </listitem>
          <listitem id="ch0131s0000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Alloui C, Sureau C, Laperche S.</emphasis> 2012. Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>338–345.</para>
          </listitem>
          <listitem id="ch0131s0000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Chotiyaputta W, Lok AS.</emphasis> 2009. Hepatitis B virus variants. <citetitle><emphasis>Nat Rev Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">6:</emphasis>453–462.</para>
          </listitem>
          <listitem id="ch0131s0000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F.</emphasis> 2007. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>3948–3953.</para>
          </listitem>
          <listitem id="ch0131s0000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Hendrickson B, Kamili S, Timmons T, Iwen PC, Pedati C, Safranek T.</emphasis> 2018. Notes from the Field: false-negative hepatitis B surface antigen test results in a hemodialysis patient—Nebraska, 2017. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">67:</emphasis>311–312.</para>
          </listitem>
          <listitem id="ch0131s0000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, Andersson MI.</emphasis> 2017. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0181267.</para>
          </listitem>
          <listitem id="ch0131s0000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Avellon A, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S, Martin D, McPherson S, Munoz-Chimeno M, Ryder S, Slapak G, Ryan P, Valbuena M, Kennedy PT.</emphasis> 2020. Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>25862.</para>
          </listitem>
          <listitem id="ch0131s0000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Roth WK.</emphasis> 2019. History and future of nucleic acid amplification technology blood donor testing. <citetitle><emphasis>Transfus Med Hemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>67–75.</para>
          </listitem>
          <listitem id="ch0131s0000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH.</emphasis> 2016. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg. <citetitle><emphasis>Am J Gastroenterol</emphasis></citetitle> <emphasis role="strong">111:</emphasis>1286–1294.</para>
          </listitem>
          <listitem id="ch0131s0000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Dachlan EG, Nugraheni C, Rahniayu A, Aldika Akbar MI.</emphasis> 2020. Quantitative HBsAg and qualitative HBeAg predicts intrauterine placental infection and umbilical blood cord in pregnant women. <citetitle><emphasis>J Family Reprod Health</emphasis></citetitle> <emphasis role="strong">14:</emphasis>106–115.</para>
          </listitem>
          <listitem id="ch0131s0000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Peng S, Wan Z, Liu T, Wang Y, Chen H, Li X, Du Y.</emphasis> 2020. Quantitative hepatitis B surface antigen predicts hepatitis B transmission in infants born to e antigen-positive mothers. <citetitle><emphasis>J Clin Gastroenterol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>76–82.</para>
          </listitem>
          <listitem id="ch0131s0000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Ahmed FA, Bajaifar MS, Ahmed MA, Alalwan A, Sanai FA, Albeladi K, Aljumah AA, Sanai FM.</emphasis> 2019. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients. <citetitle><emphasis>Saudi J Gastroenterol</emphasis></citetitle> <emphasis role="strong">25:</emphasis>286–292.</para>
          </listitem>
          <listitem id="ch0131s0000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Seiz PL, Mohr C, Wilkinson DE, Ziebuhr J, Schüttler CG, Gerlich WH, Glebe D.</emphasis> 2016. Characterization of the 3rd International Standard for hepatitis B virus surface antigen (HBsAg). <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">82:</emphasis>166–172.</para>
          </listitem>
          <listitem id="ch0131s0000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Wilkinson DE, Seiz PL, Schüttler CG, Gerlich WH, Glebe D, Scheiblauer H, Nick S, Chudy M, Dougall T, Stone L, Heath AB, Collaborative Study Group.</emphasis> 2016. International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">82:</emphasis>173–180.</para>
          </listitem>
          <listitem id="ch0131s0000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Mixson-Hayden T, Purdy MA, Ganova-Raeva L, McGovern D, Forbi JC, Kamili S.</emphasis> 2018. Evaluation of performance characteristics of hepatitis B e antigen serologic assays. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">109:</emphasis>22–28.</para>
          </listitem>
          <listitem id="ch0131s0000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Peeling RW, Boeras DI, Marinucci F, Easterbrook P.</emphasis> 2017. The future of viral hepatitis testing: innovations in testing technologies and approaches. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>699.</para>
          </listitem>
          <listitem id="ch0131s0000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Song JE, Kim DY.</emphasis> 2016. Diagnosis of hepatitis B. <citetitle><emphasis>Ann Transl Med</emphasis></citetitle> <emphasis role="strong">4:</emphasis>338.</para>
          </listitem>
          <listitem id="ch0131s0000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, Colucci G, Ghisetti V.</emphasis> 2007. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>828–834.</para>
          </listitem>
          <listitem id="ch0131s0000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, Tsongalis GJ, Wang YF, Yen-Lieberman B, Young S, Lurain NS.</emphasis> 2011. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2854–2858.</para>
          </listitem>
          <listitem id="ch0131s0000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM.</emphasis> 2008. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1716–1723.</para>
          </listitem>
          <listitem id="ch0131s0000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Pyne MT, Vest L, Clement J, Lee J, Rosvall JR, Luk K, Rossi M, Cobb B, Hillyard DR.</emphasis> 2012. Comparison of three Roche hepatitis B virus viral load assay formats. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2337–2342.</para>
          </listitem>
          <listitem id="ch0131s0000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Chevaliez S, Dauvillier C, Dubernet F, Poveda JD, Laperche S, Hézode C, Pawlotsky JM.</emphasis> 2017. The new Aptima HBV Quant Real-Time TMA Assay accurately quantifies hepatitis B virus DNA from genotypes A to F. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1211–1219.</para>
          </listitem>
          <listitem id="ch0131s0000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Bonanzinga S, Onelia F, Jackson K, Glass A, Maree L, Krügel M, Pacenti M, Gunson R, Goldstein E, García LM, Galán JC, Vilas A, Ehret R, Knechten H, Naeth G, Braun P, Obermeier M, Marlowe N, Palm MJ, Pfeifer K, Joseph AM, Dhein J, Reinhardt B, Lucic D, Chevaliez S.</emphasis> 2020. Multicenter clinical evaluation of alinity m HBV assay performance. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">129:</emphasis>104514.</para>
          </listitem>
          <listitem id="ch0131s0000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Weber J, Sahoo MK, Taylor N, Uy E, Shi RZ, Pinsky BA.</emphasis> 2019. Comparison of transcription-mediated amplification and real-time PCR assays for hepatitis B virus DNA quantitation in serum. <citetitle><emphasis>J Appl Lab Med</emphasis></citetitle> <emphasis role="strong">4:</emphasis>383–390.</para>
          </listitem>
          <listitem id="ch0131s0000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">May S, Adamska E, Tang JW.</emphasis> 2018. Evaluating the aptima HIV-1 quant Dx, HCV quant Dx and HBV quant assays against the Abbott HIV-1, HCV and HBV RealTime assays. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">106:</emphasis>7–10.</para>
          </listitem>
          <listitem id="ch0131s0000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Nyan DC, Ulitzky LE, Cehan N, Williamson P, Winkelman V, Rios M, Taylor DR.</emphasis> 2014. Rapid detection of hepatitis B virus in blood plasma by a specific and sensitive loop-mediated isothermal amplification assay. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">59:</emphasis>16–23.</para>
          </listitem>
          <listitem id="ch0131s0000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Chen CM, Ouyang S, Lin LY, Wu LJ, Xie TA, Chen JJ, Li ZX, Zhu GD, Ji TX, Pan ZY, Xia Y, Guo XG.</emphasis> 2020. Diagnostic accuracy of LAMP assay for HBV infection. <citetitle><emphasis>J Clin Lab Anal</emphasis></citetitle> <emphasis role="strong">34:</emphasis>e23281.</para>
          </listitem>
          <listitem id="ch0131s0000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R, Eurohep Pathobiology Group.</emphasis> 1999. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>68–73.</para>
          </listitem>
          <listitem id="ch0131s0000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">World Health Organization Expert Committee on Biological Standardization.</emphasis> 2016. Collaborative study to evaluate the proposed WHO 4th International Standard for Hepatitis B Virus (HBV) DNA for Nucleic Acid Amplification Technique (NAT) based assays. World Health Organization, Geneva, Switzerland.</para>
          </listitem>
          <listitem id="ch0131s0000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Locarnini S, Hatzakis A, Chen DS, Lok A.</emphasis> 2015. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">62</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S76–S86.</para>
          </listitem>
          <listitem id="ch0131s0000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Velkov S, Ott JJ, Protzer U, Michler T.</emphasis> 2018. The global hepatitis B virus genotype distribution approximated from available genotyping data. <citetitle><emphasis>Genes (Basel)</emphasis></citetitle> <emphasis role="strong">9:</emphasis>495.</para>
          </listitem>
          <listitem id="ch0131s0000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M.</emphasis> 2020. The evolution and clinical impact of hepatitis B virus genome diversity. <citetitle><emphasis>Nat Rev Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>618–634.</para>
          </listitem>
          <listitem id="ch0131s0000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Croagh CM, Desmond PV, Bell SJ.</emphasis> 2015. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. <citetitle><emphasis>World J Hepatol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>289–303.</para>
          </listitem>
          <listitem id="ch0131s0000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Bauer T, Sprinzl M, Protzer U.</emphasis> 2011. Immune control of hepatitis B virus. <citetitle><emphasis>Dig Dis</emphasis></citetitle> <emphasis role="strong">29:</emphasis>423–433.</para>
          </listitem>
          <listitem id="ch0131s0000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Rotman Y, Brown TA, Hoofnagle JH.</emphasis> 2009. Evaluation of the patient with hepatitis B. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S22–S27.</para>
          </listitem>
          <listitem id="ch0131s0000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Wong VW-S, Chan HL-Y.</emphasis> 2009. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. <citetitle><emphasis>J Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">24:</emphasis>1179–1186.</para>
          </listitem>
          <listitem id="ch0131s0000li0113" role="bibliographyEntry">
            <anchor id="ch0131s0000a0113"/>
            <para>113.<emphasis role="strong">Moretto F, Catherine FX, Esteve C, Blot M, Piroth L.</emphasis> 2020. Isolated anti-HBc: significance and management. <citetitle><emphasis>J Clin Med</emphasis></citetitle> <emphasis role="strong">9:</emphasis>E202.</para>
          </listitem>
          <listitem id="ch0131s0000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Gerlich WH, Caspari G.</emphasis> 1999. Hepatitis viruses and the safety of blood donations. <citetitle><emphasis>J Viral Hepat</emphasis></citetitle> <emphasis role="strong">6</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>6–15.</para>
          </listitem>
          <listitem id="ch0131s0000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Wu T, Kwok RM, Tran TT.</emphasis> 2017. Isolated anti-HBc: the relevance of hepatitis B core antibody—a review of new issues. <citetitle><emphasis>Am J Gastroenterol</emphasis></citetitle> <emphasis role="strong">112:</emphasis>1780–1788.</para>
          </listitem>
          <listitem id="ch0131s0000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Huzly D, Schenk T, Jilg W, Neumann-Haefelin D.</emphasis> 2008. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1298–1306.</para>
          </listitem>
          <listitem id="ch0131s0000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Raven S, Hautvast J, Steenbergen JV, Akkermans R, Weykamp C, Smits F, Hoebe C, Vossen A.</emphasis> 2017. Diagnostic performance of serological assays for anti-HBs testing: results from a quality assessment program. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">87:</emphasis>17–22.</para>
          </listitem>
          <listitem id="ch0131s0000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Centers for Disease Control and Prevention (CDC).</emphasis> 2012. Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">61</emphasis>(RR-3)<emphasis role="strong">:</emphasis>1–12.</para>
          </listitem>
          <listitem id="ch0131s0000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Hou W, Huo Z, Du Y, Wang C, Syn WK.</emphasis> 2020. Characteristics of amino acid substitutions within the “a” determinant region of hepatitis B virus in chronically infected patients with coexisting HBsAg and anti-HBs. <citetitle><emphasis>Clin Res Hepatol Gastroenterol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>923–931.</para>
          </listitem>
          <listitem id="ch0131s0000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">de Almeida Pondé RA.</emphasis> 2021. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. <citetitle><emphasis>Mol Biol Rep</emphasis></citetitle> <emphasis role="strong">48:</emphasis>843–854.</para>
          </listitem>
          <listitem id="ch0131s0000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Liu SH, Seto WK, Lai CL, Yuen MF.</emphasis> 2016. Hepatitis B: treatment choice and monitoring for response and resistance. <citetitle><emphasis>Expert Rev Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>697–707.</para>
          </listitem>
          <listitem id="ch0131s0000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Caligiuri P, Cerruti R, Icardi G, Bruzzone B.</emphasis> 2016. Overview of hepatitis B virus mutations and their implications in the management of infection. <citetitle><emphasis>World J Gastroenterol</emphasis></citetitle> <emphasis role="strong">22:</emphasis>145–154.</para>
          </listitem>
          <listitem id="ch0131s0000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Tatti KM, Korba BE, Stang HL, Peek S, Gerin JL, Tennant BC, Schinazi RF.</emphasis> 2002. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">55:</emphasis>141–150.</para>
          </listitem>
          <listitem id="ch0131s0000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Neumann-Fraune M, Beggel B, Kaiser R, Obermeier M.</emphasis> 2014. Hepatitis B virus drug resistance tools: one sequence, two predictions. <citetitle><emphasis>Intervirology</emphasis></citetitle> <emphasis role="strong">57:</emphasis>232–236.</para>
          </listitem>
          <listitem id="ch0131s0000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Guirgis BS, Abbas RO, Azzazy HM.</emphasis> 2010. Hepatitis B virus genotyping: current methods and clinical implications. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e941–e953.</para>
          </listitem>
          <listitem id="ch0131s0000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Alidjinou EK, Bocket L, Pigot V, Lambert V, Hallaert C, Canva V, Hober D.</emphasis> 2018. Sanger sequencing versus INNO-LiPA<superscript>®</superscript> HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">90:</emphasis>277–279.</para>
          </listitem>
          <listitem id="ch0131s0000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Doutreloigne J, Van Hecke E, Mercier M, Laperche S.</emphasis> 2011. Revision of interpretation criteria of the INNO-LiPA HBV genotyping assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3446.</para>
          </listitem>
          <listitem id="ch0131s0000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Mese S, Arikan M, Cakiris A, Abaci N, Gumus E, Kursun O, Onel D, Ustek D, Kaymakoglu S, Badur S, Yenen OS, Bozkaya E.</emphasis> 2013. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients. <citetitle><emphasis>J Gen Virol</emphasis></citetitle> <emphasis role="strong">94:</emphasis>2729–2738.</para>
          </listitem>
          <listitem id="ch0131s0000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Basaras M, Arrese E, Blanco S, Arroyo LS, Ruiz P, Cisterna R.</emphasis> 2013. Comparison of INNO-LIPA and TRUGENE assays for genotyping and drug-resistance mutations in chronic hepatitis B virus infection. <citetitle><emphasis>Intervirology</emphasis></citetitle> <emphasis role="strong">56:</emphasis>190–194.</para>
          </listitem>
          <listitem id="ch0131s0000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Lowe CF, Merrick L, Harrigan PR, Mazzulli T, Sherlock CH, Ritchie G.</emphasis> 2016. Implementation of next-generation sequencing for hepatitis B virus resistance testing and genotyping in a clinical microbiology laboratory. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>127–133.</para>
          </listitem>
          <listitem id="ch0131s0000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA.</emphasis> 2017. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">66:</emphasis>2013–2023.</para>
          </listitem>
          <listitem id="ch0131s0000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Gong L, Han Y, Chen L, Liu F, Hao P, Sheng J, Li XH, Yu DM, Gong QM, Tian F, Guo XK, Zhang XX.</emphasis> 2013. Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>4087–4094.</para>
          </listitem>
          <listitem id="ch0131s0000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, Reuman EC, Holmes SP, Borroto-Esoda K, Shafer RW.</emphasis> 2013. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>343–349.</para>
          </listitem>
          <listitem id="ch0131s0000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C.</emphasis> 2017. Deep sequencing in the management of hepatitis virus infections. <citetitle><emphasis>Virus Res</emphasis></citetitle> <emphasis role="strong">239:</emphasis>115–125.</para>
          </listitem>
          <listitem id="ch0131s0000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, Domingo E, Cubero M, Camós S, Ferrer-Costa C, Sánchez A, Jardí R, Schaper M, Homs M, Garcia-Cehic D, Guardia J, Esteban R, Buti M.</emphasis> 2012. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e37874.</para>
          </listitem>
          <listitem id="ch0131s0000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Yamani LN, Yano Y, Utsumi T, Juniastuti</emphasis>, <emphasis role="strong">Wandono H, Widjanarko D, Triantanoe A, Wasityastuti W, Liang Y, Okada R, Tanahashi T, Murakami Y, Azuma T, Soetjipto</emphasis>, <emphasis role="strong">Lusida MI, Hayashi Y.</emphasis> 2015. Ultradeep sequencing for detection of quasispecies variants in the major hydrophilic region of hepatitis B virus in Indonesian patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3165–3175.</para>
          </listitem>
          <listitem id="ch0131s0000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Wang S, Li H, Kou Z, Ren F, Jin Y, Yang L, Dong X, Yang M, Zhao J, Liu H, Dong N, Jia L, Chen X, Zhou Y, Qiu S, Hao R, Song H.</emphasis> 2021. Highly sensitive and specific detection of hepatitis B virus DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">27:</emphasis>443–450.</para>
          </listitem>
          <listitem id="ch0131s0000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Lee GH, Inoue M, Chong RH, Toh J, Wee SY, Loh KS, Lim SG.</emphasis> 2018. Pyrosequencing method for sensitive detection of HBV drug resistance mutations. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">90:</emphasis>1071–1079.</para>
          </listitem>
          <listitem id="ch0131s0000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T.</emphasis> 2014. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. <citetitle><emphasis>Biochem Biophys Res Commun</emphasis></citetitle> <emphasis role="strong">443:</emphasis>808–813.</para>
          </listitem>
          <listitem id="ch0131s0000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita T, Osada H, Watashi K.</emphasis> 2018. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">8:</emphasis>2769.</para>
          </listitem>
          <listitem id="ch0131s0000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Bredberg A, Bøe OW, Bredberg J, Whist JE.</emphasis> 2018. Detection of hepatitis B surface antigen in blood following vaccination. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">36:</emphasis>4963–4965.</para>
          </listitem>
          <listitem id="ch0131s0000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2018. Prevention of Hepatitis B Virus Infection in the United States: Receommendation of the Advisory Committee on Immunization Practices. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1–33. <ulink url="https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf">https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf</ulink>, accessed 17 January 2022.</para>
          </listitem>
          <listitem id="ch0131s0000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">World Health Organization.</emphasis> 2017. Guidelines on Hepatitis B and C Testing. <ulink url="https://www.who.int/publications/i/item/9789241549981">https://www.who.int/publications/i/item/9789241549981</ulink>, accessed 17 January 2022.</para>
          </listitem>
          <listitem id="ch0131s0000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou J, Chen G, Lau G.</emphasis> 2017. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. <citetitle><emphasis>Clin Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>132–136.</para>
          </listitem>
          <listitem id="ch0131s0000li0145" role="bibliographyEntry">
            <anchor id="ch0131s0000a0114"/>
            <para>145.<emphasis role="strong">Hughes SA, Wedemeyer H, Harrison PM.</emphasis> 2011. Hepatitis delta virus. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">378:</emphasis>73–85.</para>
          </listitem>
          <listitem id="ch0131s0000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Sureau C, Negro F.</emphasis> 2016. The hepatitis delta virus: replication and pathogenesis. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">64</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S102–S116.</para>
          </listitem>
          <listitem id="ch0131s0000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, Verme G.</emphasis> 1977. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">18:</emphasis>997–1003.</para>
          </listitem>
          <listitem id="ch0131s0000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W.</emphasis> 2014. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">88:</emphasis>3273–3284.</para>
          </listitem>
          <listitem id="ch0131s0000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Glenn JS, Watson JA, Havel CM, White JM.</emphasis> 1992. Identification of a prenylation site in delta virus large antigen. <citetitle><emphasis>Science</emphasis></citetitle> <emphasis role="strong">256:</emphasis>1331–1333.</para>
          </listitem>
          <listitem id="ch0131s0000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Taylor JM.</emphasis> 2020. <citetitle><emphasis>Infection by hepatitis delta virus.</emphasis></citetitle> <citetitle><emphasis>Viruses</emphasis></citetitle> <emphasis role="strong">12:</emphasis>648.</para>
          </listitem>
          <listitem id="ch0131s0000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Vlachogiannakos J, Papatheodoridis GV.</emphasis> 2020. New epidemiology of hepatitis delta. <citetitle><emphasis>Liver Int</emphasis></citetitle> <emphasis role="strong">40</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>48–53.</para>
          </listitem>
          <listitem id="ch0131s0000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM.</emphasis> 2020. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">73:</emphasis>523–532.</para>
          </listitem>
          <listitem id="ch0131s0000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Le Gal F, Brichler S, Drugan T, Alloui C, Roulot D, Pawlotsky JM, Dény P, Gordien E.</emphasis> 2017. Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1826–1841.</para>
          </listitem>
          <listitem id="ch0131s0000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, Valvano MR, Abate ML, Gioffreda D, Caviglia GP, Rizzetto M, Andriulli A.</emphasis> 2010. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>834–840.</para>
          </listitem>
          <listitem id="ch0131s0000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Caviglia GP, Rizzetto M.</emphasis> 2020. Treatment of hepatitis D: an unmet medical need. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">26:</emphasis>824–827.</para>
          </listitem>
          <listitem id="ch0131s0000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE.</emphasis> 2016. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>483–489.</para>
          </listitem>
          <listitem id="ch0131s0000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S.</emphasis> 2016. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. <citetitle><emphasis>J Hepatol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>490–498.</para>
          </listitem>
          <listitem id="ch0131s0000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çali</emphasis>ş<emphasis role="strong">kan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS.</emphasis> 2018. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1224–1236.</para>
          </listitem>
          <listitem id="ch0131s0000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.</emphasis> 2015. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1167–1174.</para>
          </listitem>
          <listitem id="ch0131s0000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Beilstein F, Blanchet M, Vaillant A, Sureau C.</emphasis> 2018. Nucleic acid polymers are active against hepatitis delta virus infection <citetitle><emphasis>in vitro.</emphasis></citetitle> <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">92:</emphasis>e01416–e01417.</para>
          </listitem>
          <listitem id="ch0131s0000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijo</emphasis>č<emphasis role="strong">evi</emphasis>ć <emphasis role="strong">H, Karimzadeh H, Roggendorf M, Vaillant A.</emphasis> 2017. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. <citetitle><emphasis>Lancet Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">2:</emphasis>877–889.</para>
          </listitem>
          <listitem id="ch0131s0000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Yurdaydin C, Keskin O, Yurdcu E, Çali</emphasis>ş<emphasis role="strong">kan A, Önem S, Karakaya F, Kalkan Ç, Karatayli E, Karatayli S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS.</emphasis> 2022. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">75:</emphasis>1551–1565.</para>
          </listitem>
          <listitem id="ch0131s0000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Brichler S, Le Gal F, Neri-Pinto F, Mansour W, Roulot D, Laperche S, Gordien E.</emphasis> 2014. Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1694–1697.</para>
          </listitem>
          <listitem id="ch0131s0000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Coller KE, Butler EK, Luk KC, Rodgers MA, Cassidy M, Gersch J, McNamara AL, Kuhns MC, Dawson GJ, Kaptue L, Bremer B, Wedemeyer H, Cloherty GA.</emphasis> 2018. Development and performance of prototype serologic and molecular tests for hepatitis delta infection. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">8:</emphasis>2095.</para>
          </listitem>
          <listitem id="ch0131s0000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Pflüger LS, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann JH, Pfefferle S, Dandri M, Schulze Zur Wiesch J, Lütgehetmann M.</emphasis> 2021. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. <citetitle><emphasis>JHEP Rep</emphasis></citetitle> <emphasis role="strong">3:</emphasis>100356.</para>
          </listitem>
          <listitem id="ch0131s0000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Wang Y, Glenn JS, Winters MA, Shen LP, Choong I, Shi YL, Bi SL, Ma LY, Zeng H, Zhang FJ.</emphasis> 2018. A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">92:</emphasis>112–117.</para>
          </listitem>
          <listitem id="ch0131s0000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Botelho-Souza LF, dos Santos AO, Borzacov LM, Honda ER, Villalobos-Salcedo JM, Vieira DS.</emphasis> 2014. Development of a reverse transcription quantitative real-time PCR-based system for rapid detection and quantitation of hepatitis delta virus in the western Amazon region of Brazil. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">197:</emphasis>19–24.</para>
          </listitem>
          <listitem id="ch0131s0000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M, Olivero A, Miklau FN, Nickel A, Reinhardt A, Dietzsch M, Kessler HH.</emphasis> 2021. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">142:</emphasis>104932.</para>
          </listitem>
          <listitem id="ch0131s0000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Cariani E, Ravaggi A, Puoti M, Mantero G, Albertini A, Primi D.</emphasis> 1992. Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. <citetitle><emphasis>Hepatology</emphasis></citetitle> <emphasis role="strong">15:</emphasis>685–689.</para>
          </listitem>
          <listitem id="ch0131s0000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Olivero A, Rosso C, Ciancio A, Abate ML, Nicolosi A, Troshina G, Armandi A, Ribaldone DG, Saracco GM, Bugianesi E, Rizzetto M, Caviglia GP.</emphasis> 2022. Clinical application of droplet digital PCR for hepatitis delta virus quantification. <citetitle><emphasis>Biomedicines</emphasis></citetitle> <emphasis role="strong">10:</emphasis>792.</para>
          </listitem>
          <listitem id="ch0131s0000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Chow SK, Atienza EE, Cook L, Prince H, Slev P, Lapé-Nixon M, Jerome KR.</emphasis> 2016. Comparison of enzyme immunoassays for detection of antibodies to hepatitis D virus in serum. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">23:</emphasis>732–734.</para>
          </listitem>
          <listitem id="ch0131s0000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Lin GY, Wu YL, Wang CS, Ko CY, Chen CH, Chen PJ, Peng PH, Hsu CW.</emphasis> 2020. Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan. <citetitle><emphasis>Virol</emphasis></citetitle> <citetitle><emphasis>J</emphasis></citetitle> <emphasis role="strong">17:</emphasis>76.</para>
          </listitem>
          <listitem id="ch0131s0000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Niro GA, Gravinese E, Martini E, Garrubba M, Facciorusso D, Conoscitore P, Di Giorgio G, Rizzetto M, Andriulli A.</emphasis> 2001. Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies. <citetitle><emphasis>Liver</emphasis></citetitle> <emphasis role="strong">21:</emphasis>254–259.</para>
          </listitem>
          <listitem id="ch0131s0000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Smedile A, Lavarini C, Crivelli O, Raimondo G, Fassone M, Rizzetto M.</emphasis> 1982. Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen: clinical significance in delta infection. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>131–138.</para>
          </listitem>
          <listitem id="ch0131s0000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group.</emphasis> 2012. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. <citetitle><emphasis>Antivir Ther</emphasis></citetitle> <emphasis role="strong">17:</emphasis>305–312.</para>
          </listitem>
          <listitem id="ch0131s0000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H, HIDIT-2 Study Group.</emphasis> 2014. Anti-HDV IgM as a marker of disease activity in hepatitis delta. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e101002.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0131s0000a0112"/>
        <beginpage pagenum="2181"/>
        <orderedlist role="notesList">
          <listitem role="noteEntry">
            <para><anchor id="ch0131s0000a0115"/><link linkend="ch0131s0000a0001">*</link>This chapter contains information presented by Yi-Wei Tang, Rebecca T. Horvat, and Marie-Louise Landry in chapter 111 of the 12th edition of this <emphasis>Manual</emphasis>.</para>
          </listitem>
        </orderedlist>
      </sect2>
    </sect1>
  </chapter>
